Platzbecker, Uwe; Santini, Valeria; Fenaux, Pierre; Sekeres, Mikkael A; Savona, Michael R; Madanat, Yazan F; Díez-Campelo, Maria; Valcárcel, David; Illmer, Thomas; Jonášová, Anna; Bělohlávková, Petra; Sherman, Laurie J; Berry, Tymara; Dougherty, Souria; Shah, Sheetal; Xia, Qi; Sun, Libo; Wan, Ying; Huang, Fei; Ikin, Annat; Navada, Shyamala; Feller, Faye; Komrokji, Rami S; Zeidan, Amer M (2024). Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. THE LANCET, vol. 403, pp. 249-260, ISSN:0140-6736 DOI   Accesso ONLINE all'editore

  Zeidan, Amer M; Ando, Kiyoshi; Rauzy, Odile; Turgut, Mehmet; Wang, Ming-Chung; Cairoli, Roberto; Hou, Hsin-An; Kwong, Yok-Lam; Arnan, Montserrat; Meers, Stef; Pullarkat, Vinod; Santini, Valeria; Malek, Kamel; Kiertsman, Flavia; Niolat, Julie; Ramos, Pedro Marques; Menssen, Hans D; Fenaux, Pierre; Miyazaki, Yasushi; Platzbecker, Uwe (2024). Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. THE LANCET. HAEMATOLOGY, vol. 11, pp. 38-50, ISSN:2352-3026 DOI  

  Sekeres, Mikkael A.; Santini, Valeria; Díez-Campelo, Maria; Komrokji, Rami S.; Fenaux, Pierre; Savona, Michael R.; Madanat, Yazan F.; Valcárcel-Ferreiras, David; Oliva, Esther Natalie; Regnault, Antoine; Creel, Kristin; Sengupta, Nishan; Dougherty, Souria; Shah, Sheetal; Sun, Libo; Wan, Ying; Navada, Shyamala; Zeidan, Amer M.; Platzbecker, Uwe (2024). Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study. LEUKEMIA & LYMPHOMA, pp. 1-6, ISSN:1042-8194 DOI  

  Extermann, Martine; Artz, Andrew; Rebollo, Maite Antonio; Klepin, Heidi D.; Krug, Utz; Loh, Kah Poh; Mims, Alice S.; Neuendorff, Nina; Santini, Valeria; Stauder, Reinhard; Vey, Norbert (2024). Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG). JOURNAL OF GERIATRIC ONCOLOGY, vol. 15, pp. 101626-101632, ISSN:1879-4068 DOI   Accesso ONLINE all'editore

  Onida, Francesco; Gagelmann, Nico; Chalandon, Yves; Kobbe, Guido; Robin, Marie; Symeonidis, Argiris; de Witte, Theo M.; Itzykson, Raphaël A.; Jentzsch, Madlen; Platzbecker, Uwe; Santini, Valeria; Sanz, Guillermo F.; Scheid, Christoph; Solary, Eric; Valent, Peter; Greco, Raffaela; Sánchez-Ortega, Isabel; Yakoub-Agha, Ibrahim; Pleyer, Lisa (2024). Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee. BLOOD, pp. 0-0, ISSN:0006-4971 DOI   Accesso ONLINE all'editore

  Winter, Susann; Schneider, Marie; Oelschlaegel, Uta; Maggioni, Giulia; Riva, Elena; Raddi, Marco Gabriele; Bencini, Sara; Peruzzi, Benedetta; Choy, Desmond; Antunes Dos Reis, Rita; Güse, Esther; Lischer, Christopher; Vera, Julio; Timms, Jessica A.; Sompairac, Nicolas; Sockel, Katja; Poloni, Antonella; Tunger, Antje; Della Porta, Matteo Giovanni; Santini, Valeria; Schmitz, Marc; Platzbecker, Uwe; Kordasti, Shahram (2024). Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms. LEUKEMIA, pp. 0-0, ISSN:0887-6924 DOI   Accesso ONLINE all'editore

  Komrokji, Rami S; Lanino, Luca; Ball, Somedeb; Bewersdorf, Jan P; Marchetti, Monia; Maggioni, Giulia; Travaglino, Erica; Al Ali, Najla H; Fenaux, Pierre; Platzbecker, Uwe; Santini, Valeria; Diez-Campelo, Maria; Singh, Avani; Jain, Akriti G; Aguirre, Luis E; Tinsley-Vance, Sarah M; Schwabkey, Zaker I; Chan, Onyee; Xie, Zhouer; Brunner, Andrew M; Kuykendall, Andrew T; Bennett, John M; Buckstein, Rena; Bejar, Rafael; Carraway, Hetty E; DeZern, Amy E; Griffiths, Elizabeth A; Halene, Stephanie; Hasserjian, Robert P; Lancet, Jeffrey; List, Alan F; Loghavi, Sanam; Odenike, Olatoyosi; Padron, Eric; Patnaik, Mrinal M; Roboz, Gail J; Stahl, Maximilian; Sekeres, Mikkael A; Steensma, David P; Savona, Michael R; Taylor, Justin; Xu, Mina L; Sweet, Kendra; Sallman, David A; Nimer, Stephen D; Hourigan, Christopher S; Wei, Andrew H; Sauta, Elisabetta; D'Amico, Saverio; Asti, Gianluca; Castellani, Gastone; Delleani, Mattia; Campagna, Alessia; Borate, Uma M; Sanz, Guillermo; Efficace, Fabio; Gore, Steven D; Kim, Tae Kon; Daver, Navel; Garcia-Manero, Guillermo; Rozman, Maria; Orfao, Alberto; Wang, Sa A; Foucar, M Kathryn; Germing, Ulrich; Haferlach, Torsten; Scheinberg, Phillip; Miyazaki, Yasushi; Iastrebner, Marcelo; Kulasekararaj, Austin; Cluzeau, Thomas; Kordasti, Shahram; van de Loosdrecht, Arjan A; Ades, Lionel; Zeidan, Amer M; Della Porta, Matteo G (2024). Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. THE LANCET. HAEMATOLOGY, vol. 11, pp. 862-872, ISSN:2352-3026 DOI  

  Stahl, Maximilian; Bewersdorf, Jan Philipp; Xie, Zhuoer; Porta, Matteo Giovanni Della; Komrokji, Rami; Xu, Mina L.; Abdel-Wahab, Omar; Taylor, Justin; Steensma, David P.; Starczynowski, Daniel T.; Sekeres, Mikkael A.; Sanz, Guillermo; Sallman, David A.; Roboz, Gail J.; Platzbecker, Uwe; Patnaik, Mrinal M.; Padron, Eric; Odenike, Olatoyosi; Nimer, Stephen D.; Nazha, Aziz; Majeti, Ravi; Loghavi, Sanam; Little, Richard F.; List, Alan F.; Kim, Tae Kon; Hourigan, Christopher S.; Hasserjian, Robert P.; Halene, Stephanie; Griffiths, Elizabeth A.; Gore, Steven D.; Greenberg, Peter; Figueroa, Maria E.; Fenaux, Pierre; Efficace, Fabio; DeZern, Amy E.; Daver, Naval G.; Churpek, Jane E.; Carraway, Hetty E.; Buckstein, Rena; Brunner, Andrew M.; Boultwood, Jacqueline; Borate, Uma; Bejar, Rafael; Bennett, John M.; Wei, Andrew H.; Santini, Valeria; Savona, Michael R.; Zeidan, Amer M. (2023). Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). BLOOD REVIEWS, vol. 62, pp. 0-0, ISSN:0268-960X DOI   Accesso ONLINE all'editore

  Itzykson, Raphael; Santini, Valeria; Thepot, Sylvain; Ades, Lionel; Chaffaut, Cendrine; Giagounidis, Aristoteles; Morabito, Margot; Droin, Nathalie; Lübbert, Michael; Sapena, Rosa; Nimubona, Stanislas; Goasguen, Jean; Wattel, Eric; Zini, Gina; Torregrosa Diaz, Jose Miguel; Germing, Ulrich; Pelizzari, Anna Maria; Park, Sophie; Jaekel, Nadja; Metzgeroth, Georgia; Onida, Francesco; Navarro, Robert; Patriarca, Andrea; Stamatoullas, Aspasia; Götze, Katharina; Puttrich, Martin; Mossuto, Sandra; Solary, Eric; Gloaguen, Silke; Chevret, Sylvie; Chermat, Fatiha; Platzbecker, Uwe; Fenaux, Pierre (2023). Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. JOURNAL OF CLINICAL ONCOLOGY, vol. 41, pp. 1888-1897, ISSN:0732-183X DOI  

  D'Amico, Saverio; Dall’Olio, Daniele; Sala, Claudia; Dall’Olio, Lorenzo; Sauta, Elisabetta; Zampini, Matteo; Asti, Gianluca; Lanino, Luca; Maggioni, Giulia; Campagna, Alessia; Ubezio, Marta; Russo, Antonio; Bicchieri, Maria Elena; Riva, Elena; Tentori, Cristina A.; Travaglino, Erica; Morandini, Pierandrea; Savevski, Victor; Santoro, Armando; Prada-Luengo, Iñigo; Krogh, Anders; Santini, Valeria; Kordasti, Shahram; Platzbecker, Uwe; Diez-Campelo, Maria; Fenaux, Pierre; Haferlach, Torsten; Castellani, Gastone; Della Porta, Matteo Giovanni (2023). Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology. JCO CLINICAL CANCER INFORMATICS, vol. 7, pp. 0-0, ISSN:2473-4276 DOI   Accesso ONLINE all'editore

  Zeidan, Amer M.; Platzbecker, Uwe; Bewersdorf, Jan Philipp; Stahl, Maximilian; Adès, Lionel; Borate, Uma; Bowen, David T; Buckstein, Rena J.; Brunner, Andrew M.; Carraway, Hetty E; Daver, Naval G.; Díez-Campelo, Maria; de Witte, Theo M; DeZern, Amy E.; Efficace, Fabio; Garcia-Manero, Guillermo; Garcia, Jacqueline S.; Germing, Ulrich; Giagounidis, Aristoteles; Griffiths, Elizabeth A; Hasserjian, Robert P; Hellström-Lindberg, Eva; Iastrebner, Marcelo C; Komrokji, Rami S.; Kulasekararaj, Austin G; Malcovati, Luca; Miyazaki, Yasushi; Odenike, Olatoyosi; Santini, Valeria; Sanz, Guillermo F.; Scheinberg, Phillip; Stauder, Reinhard; Van de Loosdrecht, Arjan A; Wei, Andrew H; Sekeres, Mikkael A.; Fenaux, Pierre (2023). Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes. BLOOD, vol. 141, pp. 2047-2061, ISSN:0006-4971 DOI  

  Bewersdorf, Jan Philipp; Xie, Zhuoer; Bejar, Rafael; Borate, Uma; Boultwood, Jacqueline; Brunner, Andrew M.; Buckstein, Rena; Carraway, Hetty E.; Churpek, Jane E.; Daver, Naval G.; Porta, Matteo Giovanni Della; DeZern, Amy E.; Fenaux, Pierre; Figueroa, Maria E.; Gore, Steven D.; Griffiths, Elizabeth A.; Halene, Stephanie; Hasserjian, Robert P.; Hourigan, Christopher S.; Kim, Tae Kon; Komrokji, Rami; Kuchroo, Vijay K.; List, Alan F.; Loghavi, Sanam; Majeti, Ravindra; Odenike, Olatoyosi; Patnaik, Mrinal M.; Platzbecker, Uwe; Roboz, Gail J.; Sallman, David A.; Santini, Valeria; Sanz, Guillermo; Sekeres, Mikkael A.; Stahl, Maximilian; Starczynowski, Daniel T.; Steensma, David P.; Taylor, Justin; Abdel-Wahab, Omar; Xu, Mina L.; Savona, Michael R.; Wei, Andrew H.; Zeidan, Amer M. (2023). Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). BLOOD REVIEWS, vol. 60, pp. 0-0, ISSN:0268-960X DOI  

  Oliva, Esther Natalie; Riva, Marta; Niscola, Pasquale; Santini, Valeria; Breccia, Massimo; Giai, Valentina; Poloni, Antonella; Patriarca, Andrea; Crisà, Elena; Capodanno, Isabella; Salutari, Prassede; Reda, Gianluigi; Cascavilla, Nicola; Ferrero, Dario; Guarini, Attilio; Tripepi, Giovanni; Iannì, Giuseppe; Russo, Emilio; Castelli, Andrea; Fattizzo, Bruno; Beltrami, Germana; Bocchia, Monica; Molteni, Alfredo; Fenaux, Pierre; Germing, Ulrich; Ricco, Alessandra; Palumbo, Giuseppe A.; Impera, Stefana; Di Renzo, Nicola; Rivellini, Flavia; Buccisano, Francesco; Stamatoullas-Bastard, Aspasia; Liberati, Anna Marina; Candoni, Anna; Delfino, Ilaria Maria; Arcadi, Maria Teresa; Cufari, Patrizia; Rizzo, Lorenzo; Bova, Irene; D'Errigo, Maria Grazia; Zini, Gina; Latagliata, Roberto (2023). Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). JOURNAL OF CLINICAL ONCOLOGY, vol. 41, pp. 4486-4496, ISSN:0732-183X DOI  

  Lanino, Luca; Restuccia, Francesco; Perego, Alessandra; Ubezio, Marta; Fattizzo, Bruno; Riva, Marta; Consagra, Angela; Musto, Pellegrino; Cilloni, Daniela; Oliva, Esther Natalie; Palmieri, Raffaele; Poloni, Antonella; Califano, Catello; Capodanno, Isabella; Itri, Federico; Elena, Chiara; Fozza, Claudio; Pane, Fabrizio; Pelizzari, Anna Maria; Breccia, Massimo; Di Bassiano, Francesco; Crisà, Elena; Ferrero, Dario; Giai, Valentina; Barraco, Daniela; Vaccarino, Antonella; Griguolo, Davide; Minetto, Paola; Quintini, Martina; Paolini, Stefania; Sanpaolo, Grazia; Sessa, Mariarosaria; Bocchia, Monica; Di Renzo, Nicola; Diral, Elisa; Leuzzi, Livia; Genua, Angelo; Guarini, Attilio; Molteni, Alfredo; Nicolino, Barbara; Occhini, Ubaldo; Rivoli, Giulia; Bono, Roberto; Calvisi, Anna; Castelli, Andrea; Di Bona, Eros; Di Veroli, Ambra; Ferrara, Felicetto; Fianchi, Luana; Galimberti, Sara; Grimaldi, Daniele; Marchetti, Monia; Norata, Marianna; Frigeni, Marco; Sancetta, Rosaria; Selleri, Carmine; Tanasi, Ilaria; Tosi, Patrizia; Turrini, Mauro; Giordano, Laura; Finelli, Carlo; Pasini, Paolo; Naldi, Ilaria; Santini, Valeria; Della Porta, Matteo Giovanni; null, null (2023). Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. AMERICAN JOURNAL OF HEMATOLOGY, vol. 98, pp. 0-0, ISSN:0361-8609 DOI  

  Zeidan, Amer M; Giagounidis, Aristoteles; Sekeres, Mikkael A; Xiao, Zhijian; Sanz, Guillermo F; Hoef, Marlies Van; Ma, Fei; Hertle, Sabine; Santini, Valeria (2023). STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. FUTURE ONCOLOGY, vol. 19, pp. 631-642, ISSN:1479-6694 DOI  

  Platzbecker, Uwe; Santini, Valeria; Komrokji, Rami S.; Zeidan, Amer M.; Garcia-Manero, Guillermo; Buckstein, Rena; Miteva, Dimana; Keeperman, Karen; Holot, Natalia; Nadal, Jose Alberto; Lai, Yinzhi; Vodala, Sadanand; Rosettani, Barbara; Giuseppi, Ana Carolina; Yucel, Aylin; Fenaux, Pierre (2023). Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. LEUKEMIA, vol. 37, pp. 2314-2318, ISSN:0887-6924 DOI  

  Platzbecker, Uwe; Della Porta, Matteo Giovanni; Santini, Valeria; Zeidan, Amer M; Komrokji, Rami S; Shortt, Jake; Valcarcel, David; Jonasova, Anna; Dimicoli-Salazar, Sophie; Tiong, Ing Soo; Lin, Chien-Chin; Li, Jiahui; Zhang, Jennie; Giuseppi, Ana Carolina; Kreitz, Sandra; Pozharskaya, Veronika; Keeperman, Karen L; Rose, Shelonitda; Shetty, Jeevan K; Hayati, Sheida; Vodala, Sadanand; Prebet, Thomas; Degulys, Andrius; Paolini, Stefania; Cluzeau, Thomas; Fenaux, Pierre; Garcia-Manero, Guillermo (2023). Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. THE LANCET, vol. 402, pp. 373-385, ISSN:0140-6736 DOI  

  Roncareggi, Samuele; Girardi, Katia; Fioredda, Francesca; Pedace, Lucia; Arcuri, Luca; Badolato, Raffaele; Bonanomi, Sonia; Borlenghi, Erika; Cirillo, Emilia; Coliva, Tiziana; Consonni, Filippo; Conti, Francesca; Farruggia, Piero; Gambineri, Eleonora; Guerra, Fabiola; Locatelli, Franco; Mancuso, Gaia; Marzollo, Antonio; Masetti, Riccardo; Micalizzi, Concetta; Onofrillo, Daniela; Piccini, Matteo; Pignata, Claudio; Raddi, Marco Gabriele; Santini, Valeria; Vendemini, Francesca; Biondi, Andrea; Saettini, Francesco (2023). A Nationwide Study of GATA2 Deficiency in Italy Reveals Novel Symptoms and Genotype–phenotype Association. JOURNAL OF CLINICAL IMMUNOLOGY, vol. 43, pp. 2192-2207, ISSN:0271-9142 DOI   Accesso ONLINE all'editore

  Germing U.; Fenaux P.; Platzbecker U.; Buckstein R.; Santini V.; Diez-Campelo M.; Yucel A.; Tang D.; Fabre S.; Zhang G.; Zoffoli R.; Ha X.; Miteva D.; Hughes C.; Komrokji R.S.; Zeidan A.M.; Garcia-Manero G. (2023). Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study. ANNALS OF HEMATOLOGY, vol. 102, pp. 311-321, ISSN:1432-0584 DOI  

  Attardi, Enrico; Andolfo, Immacolata; Russo, Roberta; Tiberi, Lucia; Raddi, Marco Gabriele; Rosato, Barbara Eleni; Marra, Roberta; Formicola, Daniela; Del Giudice, Federica; Brogi, Alice; Consagra, Angela; Amato, Cristina; Sanna, Alessandro; Artuso, Rosangela; Iolascon, Achille; Santini, Valeria (2023). PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes. AMERICAN JOURNAL OF HEMATOLOGY, vol. 98, pp. 0-0, ISSN:0361-8609 DOI  

  Shallis, Rory M; Daver, Naval G; Altman, Jessica K; Hasserjian, Robert P; Kantarjian, Hagop M; Platzbecker, Uwe; Santini, Valeria; Wei, Andrew H; Sallman, David A; Zeidan, Amer M (2023). TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. CANCER, vol. 129, pp. 175-180, ISSN:0008-543X DOI  

  Sauta, Elisabetta; Robin, Marie; Bersanelli, Matteo; Travaglino, Erica; Meggendorfer, Manja; Zhao, Lin-Pierre; Caballero Berrocal, Juan Carlos; Sala, Claudia; Maggioni, Giulia; Bernardi, Massimo; Di Grazia, Carmen; Vago, Luca; Rivoli, Giulia; Borin, Lorenza; D'Amico, Saverio; Tentori, Cristina Astrid; Ubezio, Marta; Campagna, Alessia; Russo, Antonio; Mannina, Daniele; Lanino, Luca; Chiusolo, Patrizia; Giaccone, Luisa; Voso, Maria Teresa; Riva, Marta; Oliva, Esther Natalie; Zampini, Matteo; Riva, Elena; Nibourel, Olivier; Bicchieri, Marilena; Bolli, Niccolo’; Rambaldi, Alessandro; Passamonti, Francesco; Savevski, Victor; Santoro, Armando; Germing, Ulrich; Kordasti, Shahram; Santini, Valeria; Diez-Campelo, Maria; Sanz, Guillermo; Sole, Francesc; Kern, Wolfgang; Platzbecker, Uwe; Ades, Lionel; Fenaux, Pierre; Haferlach, Torsten; Castellani, Gastone; Della Porta, Matteo Giovanni (2023). Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. JOURNAL OF CLINICAL ONCOLOGY, vol. 41, pp. 2827-2842, ISSN:0732-183X DOI  

  Calabretto, Giulia; Attardi, Enrico; Teramo, Antonella; Trimarco, Valentina; Carraro, Samuela; Mossuto, Sandra; Barilà, Gregorio; Vicenzetto, Cristina; Gasparini, Vanessa Rebecca; Crugnola, Monica; Niscola, Pasquale; Poloni, Antonella; Giai, Valentina; Gaidano, Valentina; Finelli, Carlo; Bertorelle, Roberta; Candiotto, Cinzia; Pizzi, Marco; Binotto, Gianni; Facco, Monica; Vianello, Fabrizio; Trentin, Livio; Semenzato, Gianpietro; Zambello, Renato; Santini, Valeria (2022). Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. LEUKEMIA, pp. 592-593, ISSN:1476-5551 DOI  

  Mughal T.I.; Pemmaraju N.; Bejar R.; Gale R.P.; Bose P.; Kiladjian J.-J.; Prchal J.; Royston D.; Pollyea D.; Valent P.; Brummendorf T.H.; Skorski T.; Patnaik M.; Santini V.; Fenaux P.; Kucine N.; Verstovsek S.; Mesa R.; Barbui T.; Saglio G.; Van Etten R.A. (2022). Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. HEMATOLOGICAL ONCOLOGY, pp. 0-0, ISSN:0278-0232 DOI  

  Oliva E.N.; Platzbecker U.; Garcia-Manero G.; Mufti G.J.; Santini V.; Sekeres M.A.; Komrokji R.S.; Shetty J.K.; Tang D.; Guo S.; Liao W.; Zhang G.; Ha X.; Ito R.; Lord-Bessen J.; Backstrom J.T.; Fenaux P. (2022). Health-related quality of life outcomes in patients with myelodysplastic syndromes with ring sideroblasts treated with luspatercept in the MEDALIST phase 3 trial. JOURNAL OF CLINICAL MEDICINE, vol. 11, pp. 27-32, ISSN:2077-0383 DOI  

  Zeidan, Amer M; Bewersdorf, Jan Philipp; Buckstein, Rena; Sekeres, Mikkael A; Steensma, David P; Platzbecker, Uwe; Loghavi, Sanam; Boultwood, Jacqueline; Bejar, Rafael; Bennett, John M; Borate, Uma; Brunner, Andrew M; Carraway, Hetty; Churpek, Jane E; Daver, Naval G; Della Porta, Matteo; DeZern, Amy E; Efficace, Fabio; Fenaux, Pierre; Figueroa, Maria E; Greenberg, Peter; Griffiths, Elizabeth A; Halene, Stephanie; Hasserjian, Robert P; Hourigan, Christopher S; Kim, Nina; Kim, Tae Kon; Komrokji, Rami S; Kutchroo, Vijay; List, Alan F; Little, Richard F; Majeti, Ravi; Nazha, Aziz; Nimer, Stephen D; Odenike, Olatoyosi; Padron, Eric; Patnaik, Mrinal M; Roboz, Gail J; Sallman, David A; Sanz, Guillermo; Stahl, Maximilian; Starczynowski, Daniel T; Taylor, Justin; Xie, Zhuoer; Xu, Mina; Savona, Michael R; Wei, Andrew H; Abdel-Wahab, Omar; Santini, Valeria (2022). Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. LEUKEMIA, vol. 36, pp. 2939-2946, ISSN:0887-6924 DOI  

  Buske C.; Dreyling M.; Alvarez-Larran A.; Apperley J.; Arcaini L.; Besson C.; Bullinger L.; Corradini P.; Giovanni Della Porta M.; Dimopoulos M.; D'Sa S.; Eich H.T.; Foa R.; Ghia P.; da Silva M.G.; Gribben J.; Hajek R.; Harrison C.; Heuser M.; Kiesewetter B.; Kiladjian J.J.; Kroger N.; Moreau P.; Passweg J.R.; Peyvandi F.; Rea D.; Ribera J.-M.; Robak T.; San-Miguel J.F.; Santini V.; Sanz G.; Sonneveld P.; von Lilienfeld-Toal M.; Wendtner C.; Pentheroudakis G.; Passamonti F. (2022). Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO OPEN, vol. 7, pp. 100403-100407, ISSN:2059-7029 DOI  

  Komrokji R.S.; Platzbecker U.; Fenaux P.; Zeidan A.M.; Garcia-Manero G.; Mufti G.J.; Santini V.; Diez-Campelo M.; Finelli C.; Jurcic J.G.; Greenberg P.L.; Sekeres M.A.; DeZern A.E.; Savona M.R.; Shetty J.K.; Ito R.; Zhang G.; Ha X.; Backstrom J.T.; Verma A. (2022). Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. LEUKEMIA, vol. 36, pp. 1432-1435, ISSN:0887-6924 DOI  

  Pilo F.; Cilloni D.; Della Porta M.G.; Forni G.L.; Piperno A.; Santini V.; Angelucci E. (2022). Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: It's more a matter of burden or more of exposure to toxic iron form?. LEUKEMIA RESEARCH, vol. 114, pp. 106792-106796, ISSN:0145-2126 DOI  

  Garcia-Manero, Guillermo; Mufti Obe, Ghulam J; Fenaux, Pierre; Buckstein, Rena J.; Santini, Valeria; Díez-Campelo, María; Finelli, Carlo; Ilhan, Osman; Sekeres, Mikkael A; Zeidan, Amer M.; Ito, Rodrigo; Zhang, Jennie; Rampersad, Anita; Sinsimer, Daniel; Backstrom, Jay T.; Platzbecker, Uwe; Komrokji, Rami S. (2021). Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. BLOOD, vol. online ahead of print, pp. 0-0, ISSN:0006-4971 DOI  

  Patnaik M.M.; Santini V. (2021). Targeting ineffective hematopoiesis in myelodysplastic syndromes. AMERICAN JOURNAL OF HEMATOLOGY, vol. online ahead of print, pp. 0-0, ISSN:0361-8609 DOI  

  Garcia-Manero G.; Dohner H.; Wei A.H.; La Torre I.; Skikne B.; Beach C.L.; Santini V. (2021). Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. online ahead of print, pp. 0-0, ISSN:2152-2650 DOI  

  Garcia-Manero G.; Santini V.; Almeida A.; Platzbecker U.; Jonasova A.; Silverman L.R.; Falantes J.; Reda G.; Buccisano F.; Fenaux P.; Buckstein R.; Diez Campelo M.; Larsen S.; Valcarcel D.; Vyas P.; Giai V.; Oliva E.N.; Shortt J.; Niederwieser D.; Mittelman M.; Fianchi L.; La Torre I.; Zhong J.; Laille E.; Lopes de Menezes D.; Skikne B.; Beach C.L.; Giagounidis A. (2021). Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. JOURNAL OF CLINICAL ONCOLOGY, vol. 39, pp. 1426-1436, ISSN:1527-7755 DOI  

  Fenaux P.; Haase D.; Santini V.; Sanz G.F.; Platzbecker U.; Mey U. (2021). Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, vol. 32, pp. 142-156, ISSN:0923-7534 DOI  

  Valeria Santini (2021). Advances in myelodysplastic syndrome.. CURRENT OPINION IN ONCOLOGY, vol. 33, pp. 681-686, ISSN:1040-8746 DOI   Accesso ONLINE all'editore

  Bersanelli M.; Travaglino E.; Meggendorfer M.; Matteuzzi T.; Sala C.; Mosca E.; Chiereghin C.; Di Nanni N.; Gnocchi M.; Zampini M.; Rossi M.; Maggioni G.; Termanini A.; Angelucci E.; Bernardi M.; Borin L.; Bruno B.; Bonifazi F.; Santini V.; Bacigalupo A.; Voso M.T.; Oliva E.; Riva M.; Ubezio M.; Morabito L.; Campagna A.; Saitta C.; Savevski V.; Giampieri E.; Remondini D.; Passamonti F.; Ciceri F.; Bolli N.; Rambaldi A.; Kern W.; Kordasti S.; Sole F.; Palomo L.; Sanz G.; Santoro A.; Platzbecker U.; Fenaux P.; Milanesi L.; Haferlach T.; Castellani G.; Della Porta M.G. (2021). Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. JOURNAL OF CLINICAL ONCOLOGY, vol. 39, pp. 1223-1233, ISSN:1527-7755 DOI  

  Santini V.; Lubbert M.; Wierzbowska A.; Ossenkoppele G.J. (2021). The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia. ADVANCES IN THERAPY, vol. online ahead of print, pp. 0-0, ISSN:0741-238X DOI  

  Ward G.A.; McGraw K.L.; Abbas-Aghababazadeh F.; Meyer B.S.; McLemore A.F.; Vincelette N.D.; Lam N.B.; Aldrich A.L.; Al Ali N.H.; Padron E.; Pinilla-Ibarz J.; Masala E.; Santini V.; Kosmider O.; Fontenay M.; Fenaux P.; Johnson J.; Fridley B.L.; List A.F. (2021). Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. BLOOD ADVANCES, vol. 5, pp. 2216-2228, ISSN:2473-9529 DOI  

  Zeidan A.M.; Boddu P.C.; Patnaik M.M.; Bewersdorf J.P.; Stahl M.; Rampal R.K.; Shallis R.; Steensma D.P.; Savona M.R.; Sekeres M.A.; Roboz G.J.; DeAngelo D.J.; Schuh A.C.; Padron E.; Zeidner J.F.; Walter R.B.; Onida F.; Fathi A.; DeZern A.; Hobbs G.; Stein E.M.; Vyas P.; Wei A.H.; Bowen D.T.; Montesinos P.; Griffiths E.A.; Verma A.K.; Keyzner A.; Bar-Natan M.; Navada S.C.; Kremyanskaya M.; Goldberg A.D.; Al-Kali A.; Heaney M.L.; Nazha A.; Salman H.; Luger S.; Pratz K.W.; Konig H.; Komrokji R.; Deininger M.; Cirici B.X.; Bhatt V.R.; Silverman L.R.; Erba H.P.; Fenaux P.; Platzbecker U.; Santini V.; Wang E.S.; Tallman M.S.; Stone R.M.; Mascarenhas J. (2020). Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. THE LANCET. HAEMATOLOGY, vol. 7, pp. e601-e612, ISSN:2352-3026 DOI  

  Santini V.; Fenaux P.; Giagounidis A.; Platzbecker U.; List A.F.; Haferlach T.; Zhong J.; Wu C.; Mavrommatis K.; Beach C.L.; MacBeth K.J.; Almeida A. (2020). Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients. LEUKEMIA, pp. 0-0, ISSN:0887-6924 DOI  

  Stojkov K.; Silzle T.; Stussi G.; Schwappach D.; Bernhard J.; Bowen D.; Cerma J.; Dinmohamed A.G.; Eeltink C.; Eggmann S.; Fenaux P.; Germing U.; Haschke M.; Hellstrom-Lindberg E.; Heger M.; Van De Loosdrecht A.A.; Passweg J.; Pfeilstocker M.; Platzbecker U.; Malcovati L.; De Almeida A.O.M.; Mittelman M.; Morgenthaler C.; Steensma D.P.; Santini V.; Stauder R.; Symeonidis A.; Schar S.; Maddox C.; De Witte T.; Bohlius J.; Bonadies N. (2020). Guideline-based indicators for adult patients with myelodysplastic syndromes. BLOOD ADVANCES, vol. 4, pp. 4029-4044, ISSN:2473-9529 DOI  

  Valeria Santini (2020). SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. HEMASPHERE, pp. 0-0, ISSN:2572-9241 DOI  

  Cilloni D.; Ravera S.; Calabrese C.; Gaidano V.; Niscola P.; Balleari E.; Gallo D.; Petiti J.; Signorino E.; Rosso V.; Panuzzo C.; Sabatini F.; Andreani G.; Dragani M.; Finelli C.; Poloni A.; Crugnola M.; Voso M.T.; Fenu S.; Pelizzari A.; Santini V.; Saglio G.; Podesta M.; Frassoni F. (2020). Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study. SCIENTIFIC REPORTS, vol. 10, pp. 9156-9163, ISSN:2045-2322 DOI  

  Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, Font P, Diez-Campelo M, Thepot S, Vellenga E, Patnaik MM, Jang JH, Varsos H, Bussolari J, Rose E, Sherman L, Sun L, Wan Y, Dougherty S, Huang F, Feller F, Rizo A, Platzbecker U (2020). Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, pp. 0-0, ISSN:0732-183X DOI   Accesso ONLINE all'editore

  Mariani M.; Mattiucci D.; Rossi E.; Mari V.; Masala E.; Giuliani A.; Santini V.; Olivieri F.; Marinelli Busilacchi E.; Mancini S.; Olivieri A.; Poloni A. (2020). Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?. FRONTIERS IN ONCOLOGY, vol. 10, pp. 0-0, ISSN:2234-943X DOI  

  Park S.; Hamel J.-F.; Toma A.; Kelaidi C.; Thepot S.; Campelo M.D.; Santini V.; Sekeres M.A.; Komrokji R.; Steensma D.; Balleari E.; Gotze K.S.; Kotsianidis I.; Guerci- Bresler A.; Stamatoullas A.; Sanz G.F.; Germing U.; Fenaux P. (2020). Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. LEUKEMIA RESEARCH, vol. 99, pp. 106472-106475, ISSN:0145-2126 DOI  

  Santini V. (2020). Enasidenib: a magic bullet for myelodysplastic syndromes?. THE LANCET. HAEMATOLOGY, vol. 7, pp. 275-276, ISSN:2352-3026 DOI  

  Crisa E.; Kulasekararaj A.G.; Adema V.; Such E.; Schanz J.; Haase D.; Shirneshan K.; Best S.; Mian S.A.; Kizilors A.; Cervera J.; Lea N.; Ferrero D.; Germing U.; Hildebrandt B.; Martinez A.B.V.; Santini V.; Sanz G.F.; Sole F.; Mufti G.J. (2020). Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. LEUKEMIA, vol. 34, pp. 2441-2450, ISSN:0887-6924 DOI  

  Fenaux P.; Platzbecker U.; Mufti G.J.; Garcia-Manero G.; Buckstein R.; Santini V.; Diez-Campelo M.; Finelli C.; Cazzola M.; Ilhan O.; Sekeres M.A.; Falantes J.F.; Arrizabalaga B.; Salvi F.; Giai V.; Vyas P.; Bowen D.; Selleslag D.; DeZern A.E.; Jurcic J.G.; Germing U.; Gotze K.S.; Quesnel B.; Beyne-Rauzy O.; Cluzeau T.; Voso M.-T.; Mazure D.; Vellenga E.; Peter L.G.; Hellstrom-Lindberg E.; Zeidan A.M.; Ades L.; Verma A.; Savona M.R.; Laadem A.; Benzohra A.; Zhang J.; Rampersad A.; Dunshee D.R.; Linde P.G.; Sherman M.L.; Komrokji R.S.; List A.F. (2020). Luspatercept in patients with lower-risk myelodysplastic syndromes. THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 382, pp. 140-151, ISSN:0028-4793 DOI  

  Santini V.; Almeida A.; Giagounidis A.; Skikne B.; Beach C.L.; Weaver J.; Tu N.; Fenaux P. (2020). Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. LEUKEMIA & LYMPHOMA, vol. 61, pp. 1475-1483, ISSN:1042-8194 DOI  

  Valeria Santini (2020). Sindromi mielodisplastiche -Corso di malattie del sangue e degli organi linfopoietici. In: Santini V, Tura S, Cavo M, Zinzani PL. Corso di malattie del sangue e degli organi emopoietici, pp. 184-198, Bologna: Società Editirce Esculapio, ISBN:978-88-9385-203-6. Accesso ONLINE all'editore

  Valeria Santini (2020). Sindromi mielodisplastiche-in Ematologia- per medicina, scienze biologiche, biotecnologie mediche. In: Santini V, Giuliani N, Olivieri A. Ematologia, pp. 215-228, Napoli: Idelson Gnocchi, ISBN:978-88-7947-709-3. Accesso ONLINE all'editore

  Bernard E.; Nannya Y.; Hasserjian R.P.; Devlin S.M.; Tuechler H.; Medina-Martinez J.S.; Yoshizato T.; Shiozawa Y.; Saiki R.; Malcovati L.; Levine M.F.; Arango J.E.; Zhou Y.; Sole F.; Cargo C.A.; Haase D.; Creignou M.; Germing U.; Zhang Y.; Gundem G.; Sarian A.; van de Loosdrecht A.A.; Jadersten M.; Tobiasson M.; Kosmider O.; Follo M.Y.; Thol F.; Pinheiro R.F.; Santini V.; Kotsianidis I.; Boultwood J.; Santos F.P.S.; Schanz J.; Kasahara S.; Ishikawa T.; Tsurumi H.; Takaori-Kondo A.; Kiguchi T.; Polprasert C.; Bennett J.M.; Klimek V.M.; Savona M.R.; Belickova M.; Ganster C.; Palomo L.; Sanz G.; Ades L.; Della Porta M.G.; Smith A.G.; Werner Y.; Patel M.; Viale A.; Vanness K.; Neuberg D.S.; Stevenson K.E.; Menghrajani K.; Bolton K.L.; Fenaux P.; Pellagatti A.; Platzbecker U.; Heuser M.; Valent P.; Chiba S.; Miyazaki Y.; Finelli C.; Voso M.T.; Shih L.-Y.; Fontenay M.; Jansen J.H.; Cervera J.; Atsuta Y.; Gattermann N.; Ebert B.L.; Bejar R.; Greenberg P.L.; Cazzola M.; Hellstrom-Lindberg E.; Ogawa S.; Papaemmanuil E. (2020). Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. NATURE MEDICINE, vol. online ahead of print, pp. 0-0, ISSN:1078-8956 DOI  

  Platzbecker U.; Fenaux P.; Ades L.; Giagounidis A.; Santini V.; Van De Loosdrecht A.A.; Bowen D.; De Witte T.; Garcia-Manero G.; Hellstrom-Lindberg E.; Germing U.; Stauder R.; Malcovati L.; Sekeres M.A.; Steensma D.P.; Gloaguen S. (2019). Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. BLOOD, vol. 133, pp. 1020-1030, ISSN:0006-4971 DOI  

  Messa E.; Gioia D.; Masiera E.; Castiglione A.; Ceccarelli M.; Salvi F.; Danise P.; Sanna A.; Allione B.; Balleari E.; Poloni A.; Cametti G.; Ferrero D.; Tassara R.; Finelli C.; Bonferroni M.; Musto P.; Saglio G.; Levis A.; Santini V. (2019). Effects of erythropoiesis-stimulating agents on overall survival of international prognostic scoring system low/intermediate-1 risk, transfusion-inde-pendent myelodysplastic syndrome patients: A cohort study. HAEMATOLOGICA, vol. 104, pp. e4-e8, ISSN:0390-6078 DOI   Accesso ONLINE all'editore

  Niyongere S.; Lucas N.; Zhou J.-M.; Sansil S.; Pomicter A.D.; Balasis M.E.; Robinson J.; Kroeger J.; Zhang Q.; Zhao Y.L.; Ball M.; Komrokji R.; List A.; Deininger M.W.; Fridley B.L.; Santini V.; Solary E.; Padron E. (2019). Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. LEUKEMIA, vol. 33, pp. 205-216, ISSN:0887-6924 DOI   Accesso ONLINE all'editore

  Bondu S.; Alary A.-S.; Lefevre C.; Houy A.; Jung G.; Lefebvre T.; Rombaut D.; Boussaid I.; Bousta A.; Guillonneau F.; Perrier P.; Alsafadi S.; Wassef M.; Margueron R.; Rousseau A.; Droin N.; Cagnard N.; Kaltenbach S.; Winter S.; Kubasch A.-S.; Bouscary D.; Santini V.; Toma A.; Hunault M.; Stamatoullas A.; Gyan E.; Cluzeau T.; Platzbecker U.; Ades L.; Puy H.; Stern M.-H.; Karim Z.; Mayeux P.; Nemeth E.; Park S.; Ganz T.; Kautz L.; Kosmider O.; Fontenay M. (2019). A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. SCIENCE TRANSLATIONAL MEDICINE, vol. 11, pp. eaav5467-eaav5470, ISSN:1946-6234 DOI   Accesso ONLINE all'editore

  Santini V.; Ossenkoppele G.J. (2019). Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 140, pp. 1-7, ISSN:1040-8428 DOI   Accesso ONLINE all'editore

  Garcia-Manero G.; Almeida A.; Fenaux P.; Gattermann N.; Giagounidis A.; Goldberg S.L.; Ozawa K.; Weaver J.; Santini V. (2019). Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 19, pp. 213-219, ISSN:2152-2650 DOI   Accesso ONLINE all'editore

  Girmenia C.; Candoni A.; Delia M.; Latagliata R.; Molteni A.; Oliva E.N.; Palumbo G.A.; Poloni A.; Salutari P.; Santini V.; Voso M.T.; Musto P. (2019). Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. BLOOD REVIEWS, vol. 34, pp. 16-25, ISSN:0268-960X DOI   Accesso ONLINE all'editore

  Santini V. (2019). How I treat MDS after hypomethylating agent failure. BLOOD, vol. 133, pp. 521-529, ISSN:0006-4971 DOI   Accesso ONLINE all'editore

  Santini, Valeria; Valcárcel, David; Platzbecker, Uwe; Komrokji, Rami S; Cleverly, Ann; Lahn, Michael M; Janssen, Jan; Zhao, Yumin; Chiang, Alan; Giagounidis, Aristoteles; Guba, Susan C; Sridharan, Ashwin; Gueorguieva, Ivelina; Girvan, Alicia; da Silva Ferreira, Mariana; Bhagat, Tushar D; Pradhan, Kith; Steidl, Ulrich; Will, Britta; Verma, Amit (2019). Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. CLINICAL CANCER RESEARCH, vol. 25, pp. 6976-6985, ISSN:1078-0432 DOI  

  Stahl M.; DeVeaux M.; Montesinos P.; Itzykson R.; Ritchie E.K.; Sekeres M.A.; Barnard J.; Podoltsev N.A.; Brunner A.; Komrokji R.S.; Bhatt V.R.; Al-Kali A.; Cluzeau T.; Santini V.; Roboz G.J.; Fenaux P.; Litzow M.; Fathi A.T.; Perreault S.; Kim T.K.; Prebet T.; Vey N.; Verma V.; Germing U.; Bergua J.; Serrano J.; Gore S.D.; Zeidan A.M. (2019). Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. LEUKEMIA & LYMPHOMA, vol. 60, pp. 246-249, ISSN:1042-8194 DOI  

  Balleari E.; Filiberti R.A.; Salvetti C.; Allione B.; Angelucci E.; Bruzzone M.; Calzamiglia T.; Cavaliere M.; Cavalleri M.; Cilloni D.; Clavio M.; Crisa E.; Da Col A.; Danise P.; Pilo F.; Ferrero D.; Finelli C.; Gioia D.; Lemoli R.M.; Masiera E.; Messa E.; Miglino M.; Musto P.; Natalie Oliva E.; Poloni A.; Salvi F.; Sanna A.; Scudeletti M.; Tassara R.; Santini V. (2019). Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis. CANCER MEDICINE, vol. 8, pp. 7567-7576, ISSN:2045-7634 DOI  

  Haase D.; Stevenson K.E.; Neuberg D.; Maciejewski J.P.; Nazha A.; Sekeres M.A.; Ebert B.L.; Garcia-Manero G.; Haferlach C.; Haferlach T.; Kern W.; Ogawa S.; Nagata Y.; Yoshida K.; Graubert T.A.; Walter M.J.; List A.F.; Komrokji R.S.; Padron E.; Sallman D.; Papaemmanuil E.; Campbell P.J.; Savona M.R.; Seegmiller A.; Ades L.; Fenaux P.; Shih L.-Y.; Bowen D.; Groves M.J.; Tauro S.; Fontenay M.; Kosmider O.; Bar-Natan M.; Steensma D.; Stone R.; Heuser M.; Thol F.; Cazzola M.; Malcovati L.; Karsan A.; Ganster C.; Hellstrom-Lindberg E.; Boultwood J.; Pellagatti A.; Santini V.; Quek L.; Vyas P.; Tuchler H.; Greenberg P.L.; Bejar R. (2019). TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. LEUKEMIA, vol. 33, pp. 1747-1758, ISSN:0887-6924 DOI   Accesso ONLINE all'editore

  Santini V.; Almeida A.; Giagounidis A.; Platzbecker U.; Buckstein R.; Beach C.L.; Guo S.; Altincatal A.; Wu C.; Fenaux P. (2018). The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 18, pp. 136-144.e7, ISSN:2152-2650 DOI   Accesso ONLINE all'editore

  Itzykson R.; Fenaux P.; Bowen D.; Cross N.C.P.; Cortes J.; De Witte T.; Germing U.; Onida F.; Padron E.; Platzbecker U.; Santini V.; Sanz G.F.; Solary E.; Van De Loosdrecht A.; Malcovati L. (2018). Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations from the European Hematology Association and the European LeukemiaNet. HEMASPHERE, vol. 2, pp. e150-0, ISSN:2572-9241 DOI  

  Santini V. (2018). Of blood and bone: the sotatercept adventure. THE LANCET. HAEMATOLOGY, vol. 5, pp. e54-e55, ISSN:2352-3026 DOI   Accesso ONLINE all'editore

  Basiorka A.A.; McGraw K.L.; Abbas-Aghababazadeh F.; McLemore A.F.; Vincelette N.D.; Ward G.A.; Eksioglu E.A.; Sallman D.A.; Ali N.A.; Padron E.; Pinilla-Ibarz J.; Komrokji R.; Masala E.; Santini V.; Kosmider O.; Fontenay M.; Fenaux P.; Sokol L.; Wei S.; Fridley B.; List A.F. (2018). Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. THE LANCET. HAEMATOLOGY, vol. 5, pp. e393-e402, ISSN:2352-3026 DOI   Accesso ONLINE all'editore

  Duchmann M.; Yalniz F.F.; Sanna A.; Sallman D.; Coombs C.C.; Renneville A.; Kosmider O.; Braun T.; Platzbecker U.; Willems L.; Ades L.; Fontenay M.; Rampal R.; Padron E.; Droin N.; Preudhomme C.; Santini V.; Patnaik M.M.; Fenaux P.; Solary E.; Itzykson R. (2018). Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBIOMEDICINE, vol. 31, pp. 174-181, ISSN:2352-3964 DOI   Accesso ONLINE all'editore

  Stahl M.; DeVeaux M.; Montesinos P.; Itzykson R.; Ritchie E.K.; Sekeres M.A.; Majhail N.; Barnard J.; Podoltsev N.A.; Brunner A.M.; Komrokji R.S.; Bhatt V.R.; Al-Kali A.; Cluzeau T.; Santini V.; Roboz G.J.; Fenaux P.; Litzow M.; Fathi A.T.; Perreault S.; Kim T.K.; Prebet T.; Vey N.; Verma V.; Kobbe G.; Bergua J.; Serrano J.; Gore S.D.; Zeidan A.M. (2018). Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 24, pp. 1754-1758, ISSN:1083-8791 DOI   Accesso ONLINE all'editore

  Fenaux P.; Santini V.; Spiriti M.A.A.; Giagounidis A.; Schlag R.; Radinoff A.; Gercheva-Kyuchukova L.; Anagnostopoulos A.; Oliva E.N.; Symeonidis A.; Berger M.H.; Gotze K.S.; Potamianou A.; Haralampiev H.; Wapenaar R.; Milionis I.; Platzbecker U. (2018). A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. LEUKEMIA, vol. 32, pp. 2648-2658, ISSN:0887-6924 DOI   Accesso ONLINE all'editore

  Stahl M.; DeVeaux M.; Montesinos P.; Itzykson R.; Ritchie E.K.; Sekeres M.A.; Barnard J.D.; Podoltsev N.A.; Brunner A.M.; Komrokji R.S.; Bhatt V.R.; Al-Kali A.; Cluzeau T.; Santini V.; Fathi A.T.; Roboz G.J.; Fenaux P.; Litzow M.R.; Perreault S.; Kim T.K.; Prebet T.; Vey N.; Verma V.; Germing U.; Bergua J.M.; Serrano J.; Gore S.D.; Zeidan A.M. (2018). Hypomethylating agents in relapsed and refractory AML: Outcomes and their predictors in a large international patient cohort. BLOOD ADVANCES, vol. 2, pp. 923-932, ISSN:2473-9529 DOI   Accesso ONLINE all'editore

  Stahl M.; DeVeaux M.; De Witte T.; Neukirchen J.; Sekeres M.A.; Brunner A.M.; Roboz G.J.; Steensma D.P.; Bhatt V.R.; Platzbecker U.; Cluzeau T.; Prata P.H.; Itzykson R.; Fenaux P.; Fathi A.T.; Smith A.; Germing U.; Ritchie E.K.; Verma V.; Nazha A.; Maciejewski J.P.; Podoltsev N.A.; Prebet T.; Santini V.; Gore S.D.; Komrokji R.S.; Zeidan A.M. (2018). The use of immunosuppressive therapy in MDS: Clinical outcomes and their predictors in a large international patient cohort. BLOOD ADVANCES, vol. 2, pp. 1765-1772, ISSN:2473-9529 DOI   Accesso ONLINE all'editore

  Miyazaki Y.; Tuechler H.; Sanz G.; Schanz J.; Garcia-Manero G.; Sole F.; Bennett J.M.; Bowen D.; Fenaux P.; Dreyfus F.; Kantarjian H.; Kuendgen A.; Malcovati L.; Cazzola M.; Cermak J.; Fonatsch C.; Le Beau M.M.; Slovak M.L.; Santini V.; Lubbert M.; Maciejewski J.; Machherndl-Spandl S.; Magalhaes S.M.M.; Pfeilstocker M.; Sekeres M.A.; Sperr W.R.; Stauder R.; Tauro S.; Valent P.; Vallespi T.; van de Loosdrecht A.A.; Germing U.; Haase D.; Greenberg P.L. (2018). Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. LEUKEMIA RESEARCH, vol. 73, pp. 51-57, ISSN:0145-2126 DOI   Accesso ONLINE all'editore

  Santini V. (2018). Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 18, pp. 495-500, ISSN:2152-2650 DOI   Accesso ONLINE all'editore

  Dohner H.; Dolnik A.; Tang L.; Seymour J.F.; Minden M.D.; Stone R.M.; del Castillo T.B.; Al-Ali H.K.; Santini V.; Vyas P.; Beach C.L.; MacBeth K.J.; Skikne B.S.; Songer S.; Tu N.; Bullinger L.; Dombret H. (2018). Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. LEUKEMIA, vol. 32, pp. 2546-2557, ISSN:0887-6924 DOI   Accesso ONLINE all'editore

  Almeida, Antonio; Fenaux, Pierre; Garcia-Manero, Guillermo; Goldberg, Stuart L; Gröpper, Stefanie; Jonasova, Anna; Vey, Norbert; Castaneda, Carmen; Zhong, Jianhua; Beach, C L; Santini, Valeria (2018). Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. LEUKEMIA & LYMPHOMA, vol. 59, pp. 2135-2143, ISSN:1042-8194 DOI  

  Masala E, Valencia-Martinez A, Pillozzi S, Rondelli T, Brogi A, Sanna A, Gozzini A, Arcangeli A, Dello Sbarba P, Santini V (2018). Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures.. ONCOTARGET, vol. 9, pp. 10561-10571, ISSN:1949-2553 DOI  

  Arcioni F.; Roncadori A.; Di Battista V.; Tura S.; Covezzoli A.; Cundari S.; Mecucci C.; Abbadessa A.; Alterini R.; Santini V.; Cantonetti M.; Buccisano F.; Bacigalupo A.; Sessarego M.; Tonso A.; Ferrero D.; D'Ardia S.; Tarella C.; Cascavilla N.; Bassan R.; Sancetta R.; Cortelezzi A.; Reda G.; Maria D'Arco A.; De Fabritiis P.; Di Renzo N.; Falini B.; Alimena G.; Avanzini P.; Ilariucci F.; Iuliano F.; La Nasa G.; Caocci G.; Defina M.; Latte G.; Palmas A.; Levis A.; Leone G.; Teresa Voso M.; Leoni P.; Poloni A.; Fozza C.; Crugnola M.; Montanaro M.; Spedini P.; Lanza F.; Pizzuti M.; Pane F.; Paolini R.; Borin L.; Rambaldi A.; Rossi G.; Maria Pelizzari A.; Russo D.; D'Emilio A.; Ruggeri M.; Semenzato G.; Specchia G.; Tagariello G.; Sartori R.; Testore F.; Ciravegna G.; Marasca R.; Cimarosto L.; Fontanive O.; Visani G. (2018). Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 101, pp. 78-85, ISSN:0902-4441 DOI   Accesso ONLINE all'editore

  Almeida, Antonio; Fenaux, Pierre; List, Alan F.; Raza, Azra; Platzbecker, Uwe; Santini, Valeria (2017). Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). LEUKEMIA RESEARCH, vol. 52, pp. 50-57, ISSN:0145-2126 DOI   Accesso ONLINE all'editore

  Musto, Pellegrino; Maurillo, Luca; Simeon, Vittorio; Poloni, Antonella; Finelli, Carlo; Balleari, Enrico; Ricco, Alessandra; Rivellini, Flavia; Cortelezzi, Agostino; Tarantini, Giuseppe; Villani, Oreste; Mansueto, Giovanna; Milella, Maria R; Scapicchio, Daniele; Marziano, Gioacchino; Breccia, Massimo; Niscola, Pasquale; Sanna, Alessandro; Clissa, Cristina; Voso, Maria T; Fenu, Susanna; Venditti, Adriano; Santini, Valeria; Angelucci, Emanuele; Levis, Alessandro (2017). Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. BRITISH JOURNAL OF HAEMATOLOGY, vol. 177, pp. 741-750, ISSN:1365-2141 DOI  

  Buckstein, Rena; Balleari, Enrico; Wells, Richard; Santini, Valeria; Sanna, Alessandro; Salvetti, Chiara; Crisà, Elena; Allione, Bernardino; Danise, Paolo; Finelli, Carlo; Clavio, Marino; Poloni, Antonella; Salvi, Flavia; Cilloni, Daniela; Oliva, Esther Natalie; Musto, Pellegrino; Houston, Brett; Zhu, Nancy; Geddes, Michelle; Leitch, Heather; Leber, Brian; Sabloff, Mitchell; Nevill, Thomas J; Yee, Karen W; Storring, John M; Francis, Janika; Maurillo, Luca; Latagliata, Roberto; Spiriti, Maria Antonietta Aloe; Andriani, Alessandro; Piccioni, Anna Lina; Fianchi, Luana; Fenu, Susanna; Gumenyuk, Svitlana; Buccisano, Francesco (2017). ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems. AMERICAN JOURNAL OF HEMATOLOGY, vol. 92, pp. 1037-1046, ISSN:1096-8652 DOI  

  Cluzeau, Thomas; McGraw, Kathy L; Irvine, Brittany; Masala, Erico; Ades, Lionel; Basiorka, Ashley A; Maciejewski, Jaroslaw; Auberger, Patrick; Wei, Sheng; Fenaux, Pierre; Santini, Valeria; List, Alan (2017). Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes. HAEMATOLOGICA, vol. 102, pp. 2015-2020, ISSN:1592-8721 DOI  

  Sébert, Marie; Komrokji, Rami S; Sekeres, Mikkael A; Prebet, Thomas; Cluzeau, Thomas; Santini, Valeria; Gyan, Emmanuel; Sanna, Alessandro; Ali, Najla HAl; Hobson, Sean; Eclache, Virginie; List, Alan; Fenaux, Pierre; Adès, Lionel (2017). Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. LEUKEMIA RESEARCH, vol. 63, pp. 72-77, ISSN:0145-2126 DOI  

  Della Porta, M. G; Jackson, C. H; Alessandrino, E. P; Rossi, M; Bacigalupo, A; van Lint, M. T; Bernardi, M; Allione, B; Bosi, Alberto; Guidi, S; Santini, Valeria; Malcovati, L; Ubezio, M; Milanesi, C; Todisco, E; Voso, M. T; Musto, P; Onida, F; Iori, A. P; Cerretti, R; Grillo, G; Molteni, A; Pioltelli, P; Borin, L; Angelucci, E; Oldani, E; Sica, S; Pascutto, C; Ferretti, V; Santoro, A; Bonifazi, F; Cazzola, M; Rambaldi, A. (2017). Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised international prognostic scoring system (IPSS-R). LEUKEMIA, pp. 22-29, ISSN:0887-6924 DOI  

  Santini V. (2017). Defeating anaemia in myelodysplastic syndromes: another step forward. THE LANCET ONCOLOGY, vol. 18, pp. 1290-1292, ISSN:1470-2045 DOI  

  Nazha, Aziz*; Sekeres, Mikkael A.; Komrokji, Rami; Steensma, David P.; Kantarjian, Hagop; Roboz, Gail; Fenaux, Pierre; Prebet, Thomas; Azarnia, Nozar; Zbyszewski, Patrick S.; Fruchtman, Steven M.; Santini, Valeria; Silverman, Lewis R.; Platzbecker, Uwe; Garcia-Manero, Guillermo (2017). Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care. BLOOD CANCER JOURNAL, vol. 7, pp. 644-646, ISSN:2044-5385 DOI   Accesso ONLINE all'editore

  Valencia-Martinez, Ana; Sanna, Alessandro; Masala, Erico; Contini, Elisa; Brogi, Alice; Gozzini, Antonella; Santini, Valeria (2017). Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia. HAEMATOLOGICA, vol. 102, pp. e332-E335, ISSN:1592-8721 DOI  

  Varaldo, Riccardo; Raiola, Anna Maria; Di Grazia, Carmen; Aquino, Sara; Beltrami, Germana; Bregante, Stefania; Cruciani, Fabio; Dominietto, Alida; Ghiso, Anna; Giannoni, Livia; Gualandi, Francesca; Ibatici, Adalberto; Lamparelli, Teresa; Marani, Carlo; Van Lint, Maria Teresa; Santini, Valeria; Bacigalupo, Andrea; Angelucci, Emanuele (2017). Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome. AMERICAN JOURNAL OF HEMATOLOGY, pp. 0-0, ISSN:0361-8609 DOI  

  Oliva, Esther N; Alati, Caterina; Santini, Valeria; Poloni, Antonella; Molteni, Alfredo; Niscola, Pasquale; Salvi, Flavia; Sanpaolo, Grazia; Balleari, Enrico; Germing, Ulrich; Fenaux, Pierre; Stamatoullas, Aspasia; Palumbo, Giuseppe A; Salutari, Prassede; Impera, Stefana; Avanzini, Paolo; Cortelezzi, Agostino; Liberati, Anna Marina; Carluccio, Paola; Buccisano, Francesco; Voso, Maria Teresa; Mancini, Stefano; Kulasekararaj, Austin; Morabito, Fortunato; Bocchia, Monica; Cufari, Patrizia; Spiriti, Maria Antonietta Aloe; Santacaterina, Irene; D'Errigo, Maria Grazia; Bova, Irene; Zini, Gina; Latagliata, Roberto (2017). Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. THE LANCET. HAEMATOLOGY, vol. 4, pp. e127-e136, ISSN:2352-3026 DOI   Accesso ONLINE all'editore

  Park, Sophie; Hamel, Jean-François; Toma, Andrea; Kelaidi, Charikleia; Thépot, Sylvain; Campelo, Maria Diez; Santini, Valeria; Sekeres, Mikkael A.; Balleari, Enrico; Kaivers, Jennifer; Sapena, Rosa; Götze, Katharina; Müller-Thomas, Catharina; Beyne-Rauzy, Odile; Stamatoullas, Aspasia; Kotsianidis, Ioannis; Komrokji, Rami; Steensma, David P.; Fensterl, Jaime; Roboz, Gail J.; Bernal, Teresa; Ramos, Fernando; Calabuig, Marisa; Guerci-Bresler, Agnès; Bordessoule, Dominique; Cony-Makhoul, Pascale; Cheze, Stéphane; Wattel, Eric; Rose, Christian; Vey, Norbert; Gioia, Daniela; Ferrero, Dario; Gaidano, Gianluca; Cametti, Giovanni; Pane, Fabrizio; Sanna, Alessandro; Germing, Ulrich; Sanz, Guillermo F.; Dreyfus, François; Fenaux, Pierre (2017). Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. JOURNAL OF CLINICAL ONCOLOGY, vol. 35, pp. 0-o, ISSN:0732-183X DOI  

  Santini V. (2017). First-line Therapeutic Strategies for Myelodysplastic Syndromes. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 17, pp. S31-S36, ISSN:2152-2650 DOI  

  Guryanova, O.A.; Lieu, Y.K.; Garrett-Bakelman, F.E.; Spitzer, B.; Glass, J.L.; Shank, K.; Martinez, A.B.V.; Rivera, S.A.; Durham, B.H.; Rapaport, F.; Keller, M.D.; Pandey, S.; Bastian, L.; Tovbin, D.; Weinstein, A.R.; Teruya-Feldstein, J.; Abdel-Wahab, O.; Santini, V.; Mason, C.E.; Melnick, A.M.; Mukherjee, S; Levine, R.L. (2016). Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. LEUKEMIA, vol. 30, pp. 1133-1142, ISSN:0887-6924 DOI   Accesso ONLINE all'editore

  Gyan, Emmanuel; Andrieu, Valérie; Sanna, Alessandro; Caille, Agnès; Schemenau, Jennifer; Sudaka, Isabelle; Siguret, Virginie; Malet, Michèle; Park, Sophie; Bordessoule, Dominique; Mairesse, Jacques; Gelsi-Boyer, Véronique; Cheze, Stéphane; Beyne-Rauzy, Odile; Sébert, Marie; Sapena, Rosa; Zerazhi, Hacene; Legros, Laurence; Guerci-Bresler, Agnès; Amé, Shanti Natarjan; Germing, Ulrich; Santini, Valeria; Salvi, Flavia; Gioia, Daniela; Lunghi, Monia; Dreyfus, François; Fenaux, Pierre (2016). Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. BRITISH JOURNAL OF HAEMATOLOGY, vol. 175, pp. 975-979, ISSN:0007-1048 DOI   Accesso ONLINE all'editore

  Kosmider, Olivier; Passet, Marie; Santini, Valeria; Platzbecker, Uwe; Andrieu, Valérie; Zini, Gina; Beyne-Rauzy, Odile; Guerci, Agnès; Masala, Erico; Balleari, Enrico; Bulycheva, Ekaterina; Dreyfus, François; Fenaux, Pierre; Fontenay, Michaela; Park, Sophie (2016). Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?. HAEMATOLOGICA, vol. 101, pp. 280-283, ISSN:0390-6078 DOI   Accesso ONLINE all'editore

  Efficace, Fabio; Santini, Valeria; La Nasa, Giorgio; Cottone, Francesco; Finelli, Carlo; Borin, Lorenza; Quaresmini, Giulia; Di Tucci, Anna Angela; Volpe, Antonio; Cilloni, Daniela; Quarta, Giovanni; Sanpaolo, Grazia; Rivellini, Flavia; Salvi, Flavia; Molteni, Alfredo; Voso, Maria Teresa; Alimena, Giuliana; Fenu, Susanna; Mandelli, Franco; Angelucci, Emanuele (2016). Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: A prospective study to assess the impact of iron chelation therapy. BMJ SUPPORTIVE & PALLIATIVE CARE, vol. 6, pp. 80-88, ISSN:2045-435X DOI   Accesso ONLINE all'editore

  Santini, Valeria; Almeida, Antonio; Giagounidis, Aristoteles; Gröpper, Stefanie; Jonasova, Anna; Vey, Norbert; Mufti, Ghulam J.; Buckstein, Rena; Mittelman, Moshe; Platzbecker, Uwe; Shpilberg, Ofer; Ram, Ron; Cañizo, Consuelo Del; Gattermann, Norbert; Ozawa, Keiya; Risueño, Alberto; Macbeth, Kyle J.; Zhong, Jianhua; Séguy, Francis; Hoenekopp, Albert; Beach, C.L.; Fenaux, Pierre (2016). Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. JOURNAL OF CLINICAL ONCOLOGY, vol. 34, pp. 2988-2996, ISSN:0732-183X DOI   Accesso ONLINE all'editore

  Santini, Valeria (2016). Treatment of low-risk myelodysplastic syndromes. HEMATOLOGY, vol. 2016, pp. 462-469, ISSN:1520-4391 DOI  

  Negoro, E.; Radivoyevitch, T.; Polprasert, C.; Adema, V.; Hosono, N.; Makishima, H.; Przychodzen, B.; Hirsch, C.; Clemente, M.J.; Nazha, A.; Santini, V.; Mcgraw, K.L.; List, A.F.; Sole, F.; Sekeres, M.A.; Maciejewski, J.P. (2016). Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. LEUKEMIA, vol. 30, pp. 2405-2409, ISSN:0887-6924 DOI   Accesso ONLINE all'editore

  Garcia-Manero, Guillermo; Almeida, Antonio; Giagounidis, Aristoteles; Platzbecker, Uwe; Garcia, Regina; Voso, Maria Teresa; Larsen, Stephen R; Valcarcel, David; Silverman, Lewis R; Skikne, Barry; Santini, Valeria (2016). Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. BMC HEMATOLOGY, vol. 16, pp. 12-21, ISSN:2052-1839 DOI  

  Santini, Valeria (2015). Life after hypomethylating agents in myelodysplastic syndrome: New strategies. CURRENT OPINION IN HEMATOLOGY, vol. 22, pp. 155-162, ISSN:1065-6251 DOI   Accesso ONLINE all'editore

  Meldi, Kristen; Qin, Tingting; Buchi, Francesca; Droin, Nathalie; Sotzen, Jason; Micol, Jean-Baptiste; Selimoglu-Buet, Dorothée; Masala, Erico; Allione, Bernardino; Gioia, Daniela; Poloni, Antonella; Lunghi, Monia; Solary, Eric; Abdel-Wahab, Omar; Santini, Valeria; Figueroa, Maria E. (2015). Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. THE JOURNAL OF CLINICAL INVESTIGATION, vol. 125, pp. 1857-1872, ISSN:0021-9738 DOI   Accesso ONLINE all'editore

  Nolte, Florian; Angelucci, Emanuele; Breccia, Massimo; Gattermann, Norbert; Santini, Valeria; Vey, Norbert; Hofmann, Wolf-Karsten (2015). Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations. LEUKEMIA RESEARCH, vol. 39, pp. 1028-1033, ISSN:0145-2126 DOI   Accesso ONLINE all'editore

  Russo, D; Malagola, M.; Skert, C.; Cancelli, V.; Turri, D.; Pregno, P.; Bergamaschi, M.; Fogli, M.; Testoni, N.; De Vivo, A.; Castagnetti, F.; Pungolino, E.; Stagno, F.; Breccia, M.; Martino, B.; Intermesoli, T.; Cambrin, G.R.; Nicolini, G.; Abruzzese, E.; Tiribelli, M.; Bigazzi, C.; Usala, E.; Russo, S.; Russo-Rossi, A.; Lunghi, M.; Bocchia, M.; D'Emilio, A.; Santini, V.; Girasoli, M.; Di Lorenzo, R.; Bernardi, S.; Di Palma, A.; Cesana, B.M.; Soverini, S.; Martinelli, G.; Rosti, G.; Baccarani, M. (2015). Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. BLOOD CANCER JOURNAL, vol. 5, pp. e347-e353, ISSN:2044-5385 DOI   Accesso ONLINE all'editore

  Castagnetti, Fausto; Gugliotta, G.; Baccarani, M.; Breccia, M.; Specchia, G.; Levato, L.; Abruzzese, E.; Rossi, G.; Iurlo, A.; Martino, B.; Pregno, P.; Stagno, F.; Cuneo, A.; Bonifacio, M.; Gobbi, M.; Russo, D.; Gozzini, A.; Tiribelli, M.; De Vivo, A.; Alimena, G.; Cavo, M.; Martinelli, G.; Pane, F.; Saglio, G.; Rosti, G.; Salvi, F.; Pini, M.; Leoni, P.; Rupoli, S.; Galieni, P.; Bigazzi, C.; Cantore, N.; Palmieri, F.; Albano, F.; Russo Rossi, A.; Rambaldi, A.; Intermesoli, T.; Palandri, F.; Testoni, N.; Luatti, S.; Soverini, S.; Iacobucci, I.; Bochicchio, M.T.; Apolinari, M.; Fogli, M.; Cervello, I.; Capucci, A.; Malagola, M.; Malpignano, A.; Girasoli, M.; Angelucci, E.; Usala, E.; Storti, S.; De Biasi, E.; Tagariello, G.; Sartori, R.; Di Raimondo, F.; Vigneri, P.; Impera, S.; Molica, S.; Lanza, F.; Viganò, C.; Grasso, M.; Rapezzi, D.; Cavazzini, F.; Bosi, A.; Santini, V.; Capalbo, S.F.; Spinosa, G.; Pierri, I.; Bergamaschi, M.; Carella, A.M.; Bacigalupo, A.; De Blasio, A.; Ciccone, F.; Di Renzo, N.; Musolino, C.; Russo, S.; Cortelezzi, A.; Morra, E.; Pungolino, E.M.; Luppi, M.; Marasca, R.; Pogliani, E.M.; Gambacorti-Passerini, C.; Luciano, L.; Ferrara, F.; Annunziata, M.; Latte, G.; Noli, D.; Rege-Cambrin, G.; Fava, C.; Semenzato, G.; Binotto, G.; Fabbiano, F.; Turri, D.; Siragusa, S.; Caracciolo, C.; Musso, M.; Porretto, F.; Aversa, F.; Crugnola, M.; Cazzola, M.; Orlandi, E.; Falini, B.; Falzetti, F.; Visani, G.; Isidori, A.; Fioritoni, G.; Di Lorenzo, R.; Vallisa, D.; Trabacchi, E.; Petrini, M.; Galimberti, S.; Pizzuti, M.; Zaccaria, A.; Salvucci, M.; Ronco, F.; Ielo, D.; Merli, F.; Avanzini, P.; Tosi, P.; Merli, A.; Musto, P.; De Stefano, V.; Sica, S.; Latagliata, R.; De Fabritiis, P.; Trawiska, M.; Majolino, I.; Pacilli, L.; Ronci, B.; Cedrone, M.; Petti, M.C.; Pisani, F.; Tafuri, A.; Montefusco, E.; Iuliano, F.; Dore, F.; Pardini, S.; Bocchia, M.; Defina, M.; Liberati, A.M.; Luzzi, D.; Boccadoro, M.; Ferrero, D.; Vitolo, U.; Gherlinzoni, F.; Calistri, E.; Fanin, R.; Pizzolo, G.; Meneghini, V.; Rodighiero, F.; D'Emilio, A. (2015). Differences among young adults, adults and elderly chronic myeloid leukemia patients. ANNALS OF ONCOLOGY, vol. 26, pp. 185-192, ISSN:0923-7534 DOI   Accesso ONLINE all'editore

  Santini, Valeria (2015). Anemia as the Main Manifestation of Myelodysplastic Syndromes. SEMINARS IN HEMATOLOGY, vol. 52, pp. 348-356, ISSN:0037-1963 DOI   Accesso ONLINE all'editore

  Santini, Valeria; Fenaux, Pierre (2015). Treatment of Myelodysplastic Syndrome with Thrombomimetic Drugs. SEMINARS IN HEMATOLOGY, vol. 52, pp. 38-45, ISSN:0037-1963 DOI   Accesso ONLINE all'editore

  Santini, Valeria (2015). On Raising the "Dust of Blood": From Unrevealing Thrombopoiesis to Treatment of Thrombocytopenias With Thrombomimetic Drugs. SEMINARS IN HEMATOLOGY, vol. 52, pp. 1-3, ISSN:0037-1963 DOI   Accesso ONLINE all'editore

  Platzbecker, Uwe; Wong, Raymond S.M.; Verma, Amit; Abboud, Camille; Araujo, Sergio; Chiou, Tzeon-Jye; Feigert, John; Yeh, Su-Peng; Götze, Katharina; Gorin, Norbert-Claude; Greenberg, Peter; Kambhampati, Suman; Kim, Yoo-Jin; Lee, Je-Hwan; Lyons, Roger; Ruggeri, Marco; Santini, Valeria; Cheng, Gregory; Jang, Jun Ho; Chen, Chien-Yuan; Johnson, Brendan; Bennett, John; Mannino, Frank; Kamel, Yasser Mostafa; Stone, Nicole; Dougherty, Souria; Chan, Geoffrey; Giagounidis, Aristoteles (2015). Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: A multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. THE LANCET. HAEMATOLOGY, vol. 2, pp. e417-e426, ISSN:2352-3026 DOI   Accesso ONLINE all'editore

  Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V. (2014). Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.. EPIGENETICS, vol. 9, pp. 387-395, ISSN:1559-2294 DOI  

  Valencia A; Masala E; Rossi A; Martino A; Sanna A; Buchi F; Canzian F; Cilloni D; Gaidano V; Voso MT; Kosmider O; Fontenay M; Gozzini A; Bosi A; Santini V. (2014). Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.. LEUKEMIA, vol. 28, pp. 621-628, ISSN:0887-6924 DOI   Accesso ONLINE all'editore

  VALENCIA MARTINEZ, ANA BELEN; Masala, Erico; Rossi, A.; Martino, A.; Sanna, A.; Buchi, Francesca; Canzian, F.; Cilloni, D.; Gaidano, V.; Voso, M. T.; Kosmider, O.; Fontenay, M.; Gozzini, A.; Bosi, Alberto; Santini, Valeria (2014). Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. LEUKEMIA, vol. 28, pp. 621-628, ISSN:0887-6924 DOI   Accesso ONLINE all'editore

  Angelucci E1; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S. (2014). Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).. EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 92, pp. 527-536, ISSN:0902-4441 DOI  

  Fenaux, P.; Haase, D.; Sanz, G.F.; Santini, V.; Buske, C. (2014). Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, vol. 25, pp. 57-69, ISSN:0923-7534 DOI   Accesso ONLINE all'editore

  Alhan, Canan; Westers, Theresia M.; van der Helm, Lieke H.; Eeltink, Corien; Huls, Gerwin; Witte, Birgit I.; Buchi, Francesca; Santini, Valeria; Ossenkoppele, Gert J.; van de Loosdrecht, Arjan A. (2014). Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. CYTOMETRY. PART B, CLINICAL CYTOMETRY, vol. 86, pp. 207-215, ISSN:1552-4949 DOI  

  Temraz, Sally; Santini, Valeria; Musallam, Khaled; Taher, Ali (2014). Iron overload and chelation therapy in myelodysplastic syndromes. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 91, pp. 64-73, ISSN:1040-8428 DOI   Accesso ONLINE all'editore

  Voso, Maria Teresa; Santini, Valeria; Fabiani, Emiliano; Fianchi, Luana; Criscuolo, Marianna; Falconi, Giulia; Guidi, Francesco; Hohaus, Stefan; Leone, Giuseppe (2014). Why methylation is not a marker predictive of response to hypomethylating agents. HAEMATOLOGICA, vol. 99, pp. 613-619, ISSN:0390-6078 DOI   Accesso ONLINE all'editore

  Santini, Valeria; Prebet, Thomas; Fenaux, Pierre; Gattermann, Norbert; Nilsson, Lars; Pfeilstöcker, Michael; Vyas, Paresh; List, Alan F. (2014). Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. LEUKEMIA RESEARCH, vol. 38, pp. 1381-1391, ISSN:0145-2126 DOI   Accesso ONLINE all'editore

  V. Barbetti; A. Gozzini; G. Cheloni; I. Marzi; E. Fabiani; V. Santini; P. Dello Sbarba; E. Rovida (2013). Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO positive leukemia cells. EPIGENETICS, vol. 8, pp. 210-219, ISSN:1559-2294 DOI   Accesso ONLINE all'editore

  Santini V; Haas P (2013). MDS and Acute Myeloid Leukemias: A Biological and Therapeutical Continuum. CHAPTER 4:Supportive therapy for ineffective hematopoiesis in MDS and AML. In: Luebbert M , Gore SD. MDS and Acute Myeloid Leukemias: A Biological and Therapeutical Continuum., pp. 18-204, Bremen: UNI-MED Verlag AG, D-28323 Bremen, International Medical Publishers (London, Boston). Accesso ONLINE all'editore

  Sardnal V; Rouquette A; Kaltenbach S; Bally C; Chesnais V; Leschi C; Ades L; Santini V; Park S; Toma A; Fenaux P; Dreyfus F; Fontenay M; Kosmider O. (2013). A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).. LEUKEMIA, vol. 27, pp. 1610-1613, ISSN:0887-6924 DOI  

  Onida F; Barosi G; Leone G; Malcovati L; Morra E; Santini V; Specchia G; Tura S. (2013). Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups.. HAEMATOLOGICA, vol. 98, pp. 1344-1352, ISSN:0390-6078 DOI  

  Adès, Lionel; Santini, Valeria (2013). Hypomethylating agents and chemotherapy in MDS. BAILLIERE'S BEST PRACTICE IN CLINICAL HAEMATOLOGY, vol. 26, pp. 411-419, ISSN:1521-6926 DOI  

  Santini V; Schemenau J; Levis A; Balleari E; Sapena R; Adès L; Guerci A; Beyne-Rauzy O; Gourin MP; Cheze S; Stamatoullas A; Sanna A; Gioia D; Cametti G; Ferrero D; Raffoux E; Rose C; Poloni A; Prebet T; Legros L; Natarajan-Amé S; Fenaux P; Germing U; Dreyfus F; Park S. (2013). Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. BLOOD, vol. 122, pp. 2286-2288, ISSN:0006-4971 DOI  

  SD Gore SD, ; Fenaux, P.; Santini, Valeria; Bennett, Jm; Silverman, Lr; Seymour, Jf; Hellström Lindberg, E.; Swern, As; Beach, Cl; List, Af (2013). A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.. HAEMATOLOGICA, vol. 98, pp. 1067-1072, ISSN:0390-6078 DOI  

  Santini V; Melnick A; Maciejewski JP; Duprez E; Nervi C; Cocco L; Ford KG; Mufti G. (2013). Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.. CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 88, pp. 231-245, ISSN:1879-0461 DOI  

  Mannelli F; Bencini S; Peruzzi B; Cutini I; Sanna A; Benelli M; Magi A; Gianfaldoni G; Rotunno G; Carrai V; Gelli AM; Valle V; Santini V; Notaro R; Luzzatto L; Bosi A. (2013). A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria.. CYTOMETRY. PART B, CLINICAL CYTOMETRY, vol. 84, pp. 71-81, ISSN:1552-4949 DOI  

  Breccia M; Fianchi L; Lunghi M; Gaidano G; Levis A; Finelli C; Santini V; Musto P; Mansueto G; Oliva EN; Leoni P; Spiriti MA; Hohaus S; Leone G; Alimena G; Voso MT. (2013). Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.. LEUKEMIA & LYMPHOMA, vol. 54, pp. 1786-1787, ISSN:1042-8194 DOI  

  E. Masala; A. Valencia; F. Buchi; D. Nosi; E. Spinelli; A. Gozzini; F. Sassolini; A. Sanna; S. Zecchi; A. Bosi; V. Santini (2012). Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells.. LEUKEMIA RESEARCH, vol. 36, pp. 1290-1295, ISSN:0145-2126 DOI  

  Spinelli E; Caporale R; Buchi F; Masala E; Gozzini A; Sanna A; Sassolini F; Valencia A; Bosi A; Santini V. (2012). Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.. CLINICAL CANCER RESEARCH, vol. 18, pp. 3079-3089, ISSN:1078-0432 DOI  

  Fianchi L; Criscuolo M; Breccia M; Maurillo L; Salvi F; Musto P; Mansueto G; Gaidano G; Finelli C; Aloe-Spiriti A; Santini V; Greco M; Hohaus S; Leone G; Voso MT (2012). High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.. LEUKEMIA & LYMPHOMA, vol. 54, pp. 658-661, ISSN:1042-8194 DOI  

  Breccia M; Fianchi L; Lunghi M; Gaidano G; Levis A; Finelli C; Santini V; Musto P; Mansueto G; Oliva EN; Leoni P; Spiriti AA; Hohaus S; Leone G; Alimena G; Voso MT (2012). Newly Proposed t-MDS Prognostic Score Predicts Significant Differences in Overall Survival and Leukemia-Free Survival in Patients Treated with Azacitidine.. LEUKEMIA & LYMPHOMA, vol. 54, pp. 1786-1787, ISSN:1042-8194 DOI  

  Oliva EN; Finelli C; Santini V; Poloni A; Liso V; Cilloni D; Impera S; Terenzi A; Levis A; Cortelezzi A; Ghio R; Musto P; Semenzato G; Clissa C; Lunghi T; Trappolini S; Gaidano V; Salvi F; Reda G; Villani O; Binotto G; Cufari P; Cavalieri E; Spiriti MA. (2012). Quality of life and physicians' perception in myelodysplastic syndromes.. AMERICAN JOURNAL OF BLOOD RESEARCH, vol. 2, pp. 136-147, ISSN:2160-1992

  V.Santini (2012). Capitolo 4. Sindromi mielodisplastiche. pp 65-98. In: S.Barni,PL. Zinzani. I retroscena della anemia, pp. 1-204, Roma: Il Pensiero Scientifico Editore.

  Spinelli E;Caporale R;Buchi F;Masala E;Gozzini A;Sanna A;Sassolini F;Valencia A;Bosi A;Santini V (2012). Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.. CLINICAL CANCER RESEARCH, vol. 18, pp. 3079-3089, ISSN:1078-0432 DOI  

  Fianchi L; Criscuolo M; Lunghi M; Gaidano G; Breccia M; Levis A; Finelli C; Santini V; Musto P; Oliva EN; Leoni P; Spiriti AA; D'Alò F; Hohaus S; Pagano L; Leone G; Voso MT (2012). Outcome of therapy-related myeloid neoplasms treated with azacitidine.. JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 5, pp. 44-50, ISSN:1756-8722 DOI  

  V. Santini (2012). Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins.. SEMINARS IN HEMATOLOGY, vol. 49, pp. 295-303, ISSN:0037-1963 DOI  

  Santini V (2012). Novel therapeutic strategies: hypomethylating agents and beyond.. HEMATOLOGY, vol. 2012, pp. 65-73, ISSN:1520-4391 DOI  

  Swords R; Santini V (2012). In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?. HEMATOLOGY, vol. 2012, pp. 74-75, ISSN:1520-4391 DOI  

  U.Platzbecker ; V.Santini ;GJ. Mufti ; C.Haferlach ; JP.Maciejewski ; S.Park ; F.Solé ; AA.van de Loosdrecht ; D.Haase (2012). Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop.. LEUKEMIA RESEARCH, vol. 36(3), pp. 264-270, ISSN:0145-2126 DOI  

  Buchi, Francesca; Spinelli, E; Masala, E; Gozzini, A; Sanna, A; Bosi, Alberto; Ferrari, G; Santini, Valeria (2012). Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.. LEUKEMIA RESEARCH, vol. 36, pp. 607-618, ISSN:0145-2126 DOI  

  V. Santini (2012). The quest for the perfect MDS scoring system. LEUKEMIA RESEARCH, vol. 36, pp. 125-126, ISSN:0145-2126 DOI  

  Buchi F; Spinelli E; Masala E; Gozzini A; Sanna A; Bosi A; Ferrari G; Santini V. (2012). Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.. LEUKEMIA RESEARCH, vol. 36, pp. 607-618, ISSN:0145-2126 DOI  

  M. Breccia ; F.Stagno ; A.Gozzini ; E.Abruzzese ; R.Latagliata ; AR.Rossi ; F.Sorà; R.Porrini ; P.Vigneri ; M.Trawinska ; E.Montefusco ;S. Sica ; G.Specchia ;V .Santini ; G.Alimena (2011). Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 86, pp. 523-525, ISSN:0361-8609 DOI  

  MT. Voso ; E. Fabiani ; A. Piciocchi ; C. Matteucci ; L.Brandimarte ; C. Finelli ; E. Pogliani ; E. Angelucci; G. Fioritoni ; P. Musto ; M. Greco ; M. Criscuolo ; L. Fianchi ; M. Vignetti ; V. Santini ; S. Hohaus ;C. Mecucci ; G.Leone (2011). Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine.. LEUKEMIA, vol. 25, pp. 1910-1913, ISSN:0887-6924 DOI  

  G. Visani; M. Breccia ;E. Montefusco ; E. Morra; V. Santini; A. Isidori (2011). The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. HAEMATOLOGICA, vol. 96, pp. e23-e24, ISSN:0390-6078 DOI  

  R.Latagliata ; M. Breccia ; F.Castagnetti ; F.Stagno ; L.Luciano ; A.Gozzini ; S.Ulisciani ; F.Cavazzini ; M.Annunziata ; F.Sorà ; AR.Rossi ; P.Pregno ; E.Montefusco ; E.Abruzzese ; E.Crisà ; P.Musto ; M.Tiribelli ; G.Binotto ; U.Occhini ;C. Feo ;P.Vigneri ; V.Santini ; C.Fava ; G.Rosti ; G. Alimena (2011). Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.. LEUKEMIA RESEARCH, vol. 35, pp. 1164-1169, ISSN:0145-2126 DOI  

  Buchi F; Pastorelli R; Ferrari G; Spinelli E; Gozzini A; Sassolini F; Bosi A; Tombaccini D; Santini V (2011). Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid.. LEUKEMIA RESEARCH, vol. 35, pp. 921-931, ISSN:0145-2126 DOI  

  M. Breccia ; R.Latagliata ; F.Stagno ; L.Luciano ; A.Gozzini ; F.Castagnetti ;C.Fava ; F.Cavazzini ; M.Annunziata ; A.Russo Rossi ; P.Pregno. E.Abruzzese ; P.Vigneri ; G.Rege-Cambrin ; S.Sica ; F.Pane ; V.Santini ; G.Specchia ; G.Rosti ; G.Alimena (2011). Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.. HAEMATOLOGICA, vol. 96, pp. 1457-1461, ISSN:0390-6078 DOI  

  C.Gambacorti-Passerini ; L.Antolini ; FX.Mahon ; F. Guilhot; M. Deininger ; C. Fava; A. Nagler CM.Della Casa ;E. Morra ; E.Abruzzese ; A.D'Emilio ; F.Stagno ; P.le Coutre ; R. Hurtado-Monroy ; V. Santini;B. Martino; F. Pane; F. Piccin; P.Giraldo ; S.Assouline ; MA.Durosinmi ; O.Leeksma ; EM.Pogliani ; M.Puttini ; E.Jang ; J.Reiffers ; MG.Valsecchi ;DW. Kim (2011). Multicenter independent assassment of outcomes in chronic myeloid leukemia patients treated with imatinib. JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 103, pp. 553-561, ISSN:0027-8874 DOI  

  L.R. Silverman ; P.Fenaux ; G.J.Mufti ; V.Santini ; E.Hellström-Lindberg ; N.Gattermann ; G. Sanz ; A.F. List ; S.D.Gore ; J.F. Seymour (2011). Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.. CANCER, vol. 117, pp. 2697-2702, ISSN:0008-543X DOI  

  V. Santini (2011). Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. THE ONCOLOGIST, vol. 16, pp. 35-42, ISSN:1083-7159 DOI  

  Buchi, F; Pastorelli, R; Ferrari, G; Spinelli, E; Gozzini, A; Sassolini, F; Bosi, Alberto; Tombaccini, D; Santini, Valeria (2011). Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid.. LEUKEMIA RESEARCH, vol. 35, pp. 921-931, ISSN:0145-2126 DOI  

  Santini V; Girelli D; Sanna A; Martinelli N; Duca L; Campostrini N; Cortelezzi A; Corbella M; Bosi A; Reda G; Olivieri O; Cappellini MD (2011). Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLOS ONE, vol. 6, pp. 0-0, ISSN:1932-6203 DOI  

  Musto, P., Maurillo, L., Spagnoli, A., Gozzini, A., Rivellini, F., Lunghi, M., Villani, O., Aloe-Spiriti, M.A., Venditti, A., Santini, V., Leone, G., Voso, M.T., D'Arco, A.M., Tatarelli, C., Ferrero, D., Gaidano, G., Palumbo, G., Di Raimondo, F., Oliva, E., Sanpaolo, G., Tonso, A., Santagostino, A., Filardi, N., Pollio, B., Candoni, A., Fili, C., Russo, D., Orciuolo, E., Petrini, M., Ciuffreda, L., Riezzo, A., Morabito, F., Mazza, P., Pastore, D., Specchia, G., Ferrara, F. (2010). Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. CANCER, vol. 116, pp. 1485-1494, ISSN:1045-7410 DOI  

  V. Santini; P.E. Alessandrino; E. Angelucci; G.Barosi; A. Billio ; M. Di Maio; C. Finelli ;F. Locatelli ;M. Marchetti; E. Morra; P.Musto ; G. Visani ;S. Tura (2010). Clinical management of myelodisplastic syndromes: update of SIE, SIES, GITMO pratice guidelines. LEUKEMIA RESEARCH, vol. 34(12), pp. 1576-1588, ISSN:0145-2126 DOI  

  V.Santini ; P.Fenaux ; GJ.Mufti ; E.Hellström-Lindberg ; LR.Silverman ; A.List ; SD.Gore ; JF.Seymour ; J.Backstrom ; CL.Beach (2010). Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.. EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 85(2), pp. 130-138, ISSN:0902-4441 DOI  

  M.A. Aloe Spiriti; P.Berto; A.Cortelezzi; C.Finelli; R.Ghio; A.Levis; V.Liso; P.Musto; E.N. Oliva; A.Poloni; V.Santini; G. semenzato; A.Terenzi (2010). Sindromi Mielodisplastiche. In: M.A. Aloe Spiriti, P.Berto, A.Cortelezzi, C.Finelli, R.Ghio, A.Levis, V.Liso, P.Musto, E.N. Oliva, A.Poloni, V.Santini, G. Semenzato, A.Terenzi. Sindromi mielodisplastiche, pp. 1-272, Milano: Elsevier Masson srl.

  Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR (2010). Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY, vol. 28, pp. 562-569, ISSN:0732-183X DOI  

  V. Barbetti;A.Gozzini; S.Giuntoli;M.Tanturli; V.Santini; P. Dello Sbarba; E.Rovida (2010). EPIGENETIC MODIFICATIONS IN A T(8;21) ACUTE MYELOID LEUKAEMIA CELL LINE CAUSED BY ADMINISTRATION OF TWO HDAC INHIBITORS, VPA AND SAHA. HAEMATOLOGICA, vol. 95(s3), pp. s74-s74, ISSN:0390-6078

  G.Visani ; M.Breccia ; A.Gozzini ; G.Specchia ; E.Montefusco ; E.Morra ; M.Annunziata ; A.Camera ; F.Cavazzini ; F.Stagno ; P.Pregno ; E.Usala ; V.Santini ; PP.Piccaluga ; A.Isidori (2010). Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 85(12), pp. 960-963, ISSN:0361-8609 DOI  

  JF. Seymour ; P. Fenaux ; LR. Silverman ; GJ. Mufti ; E. Hellström-Lindberg ;V. Santini ;AF. List ; SD. Gore ; J. Backstrom; D. McKenzie ; CL.Beach (2010). Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 76(3), pp. 218-227, ISSN:1040-8428 DOI  

  P.Fenaux ; D.Bowen ; N.Gattermann ; E.Hellström-Lindberg ; WK.Hofmann ; M.Pfeilstöcker ; G.Sanz ; V.Santini (2010). Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.. LEUKEMIA RESEARCH, vol. 34, pp. 1410-1416, ISSN:0145-2126 DOI  

  Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA; IRIS Investigators. Hughes T, Taylor K, Durant S, Schwarer A, Joske D, Seymour J, Grigg A, Ma D, Arthur C, Bradstock K, Joshua D, Agis H, Verhoef G, Louwagie A, Martiat P, Bosly A, Shepherd J, Shistok C, Lipton J, Forrest D, Walker I, Roy DC, Rubinger M, Bence-Bruckler I, Stewart D, Kovacs M, Turner AR, Nielsen J, Birgens H, Bjerrum O, Rousselot P, Reiffers J, Facon T, Harousseau JL, Tulliez M, Guerci A, Blaise D, Maloisel F, Michallet M, Fischer T, Hochhaus A, Andreesen R, Nerl C, Freund M, Gattermann N, Ehninger G, Niederwieser D, Ottmann OG, Peschel C, Ho AD, Neubauer A, le Coutre P, Aulitzky W, Saglio G, Baccarani M, Fanin R, Rosti G, Mandelli F, Lazzarino M, Morra E, Carella A, Petrini M, Nobile F, Liso V, Ferrara F, Rizzoli V, Fiortoni G, Martinelli G, Cornelissen J, Ossenkoppele G, Browett P, Gedde-Dahl T, Tangen JM, Dahl I, Cervantes F, Odrizoala J, Hernandez Boulda JC, Steegmann JL, Canizo C, Diaz J, Grenena A, Fernandez M, Simonsson B, Stenke L, Paul C, Bjoreman M, Malm C, Wadenvik H, Nilsson PG, Turesson I, Gratwohl A, Hess U, Solenthaler M, Goldman JM, Clark RE, Green A, Holyoake T, Lucas G, Smith G, Milligan D, Rule S, Burnett A, Kantarjian H, Silver R, Stone R, Powell B, Gabrilove J, Moroose R, Wetzler M, Bearden J, Cataland S, Rabinowitz I, Meisenberg B, Thompson K, Graziano S, Emanuel P, Gross H, Cobb P, Bhatia R, Dakhil S, Irwin AD, Issell B, Pavletic S, Kuebler P, Layhe E, Butra P, Glass J, Moore J, Grant B, Neill H, Herzig R, Burris H, Petersen B, Kalaycio M, Stirewalt D, Samlowski W, Berman E, Limentani S, Seay T, Shea T, Akard L, Smith G, Becker P, Devine S, Hart R, Veith R, Wade J, Brunvad M, Kalman L, Strickland D, Shurafa M, Bashey A, Shadduck R, Safah H, Rubenstein M, Collins R, Keller A, Tallman M, Pecora A, Agha M, Homes H, Guidice R, Druker BJ, Guilhot F, Larson RA, O'Brien S, Rowe J, Schiffer CA, Buyse M, Baccarani M, Cervantes F, Cornelissen J, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Reiffers J, Rousselot P, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Talpaz M, Taylor K, Verhoef G, Santini V (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.. LEUKEMIA, vol. 23, pp. 1054-1061, ISSN:0887-6924

  Kantarjian HM; Larson RA; Guilhot F; O'Brien SG; Mone M; Rudoltz M; Krahnke T; Cortes J; Druker BJ; International Randomized Study of Interferon and STI571 (IRIS) Investigators. Durant S; Schwarer A; Joske D; Seymour J; Grigg A; Ma D; Arthur C; Bradstock K; Joshua D; Louwagi A; Martiat P; Bosly A; Shistok C; Lipton J; Forrest D; Walker I; Roy DC; Rubinger M; Bence-Bruckler I; Stewart D; Kovacs M; Turner AR; Birgens H; Bjerrum O; Facon T; Harousseau JL; Tulliez M; Guerci A; Blaise D; Maloisel F; Michallet M; Andreesen R; Nerl C; Freund M; Gattermann N; Ehninger G; Deininger M; Ottmann O; Peschel C; Fruehauf S; Neubauer A; le Coutre P; Aulitzky W; Fanin R; Rosti G; Mandelli F; Lazzarino M; Morra E; Carella A; Petrini M; Nobile F; Liso V; Ferrara F; Rizzoli V; Fiortoni G; Martinelli G; Ossenkoppele G; Browett P; Gedde-Dahl T; Tangen JM; Dahl I; Odrizoala J; Hernandez Boulda JC; Steegman JL; Canizo C; Diaz J; Grenena A; Fernandez MN; Stenke L; Paul C; Bjoreman M; Malm C; Wadenvik H; Nilsson PG; Turesson I; Hess U; Solenthaler M; Clark RE; Green AR; Holyoake TL; Lucas GS; Smith G; Milligan DW; Rule SJ; Burnett AK; Moroose R; Wetzler M; Bearden J; Cataland S; Robinowitz I; Meisenberg B; Thompson K; Graziano S; Emanuel P; Gross H; Cobb P; Bhatia R; Dakhil S; Irwin D; Issell B; Pavletic S; Kuebler P; Layhe E; Butra P; Glass J; Moore J; Grant B; Neill H; Herzig R; Burris H; Petersen B; Kalaycio M; Stirewalt D; Samlowski W; Berman E; Limentani S; Seay T; Shea T; Akard L; Smith G; Becker P; Devine S; Hart R; Veith R; Wade J; Brunvad M; Kalman L; Strickland D; Shurafa M; Bashey A; Shadduck R; Safah H; Rubenstein M; Collins R; Keller A; Tallman M; Pecora A; Agha M; Homes H; Guidice R; Santini V. Kantarjian HM; Larson RA; Guilhot F; O'Brien SG; Mone M; Rudoltz M; Krahnke T; Cortes J; Druker BJ; International Randomized Study of Interferon and STI571 (IRIS) Investigators. Durant S; Schwarer A; Joske D; Seymour J; Grigg A; Ma D; Arthur C; Bradstock K; Joshua D; Louwagi A; Martiat P; Bosly A; Shistok C; Lipton J; Forrest D; Walker I; Roy DC; Rubinger M; Bence-Bruckler I; Stewart D; Kovacs M; Turner AR; Birgens H; Bjerrum O; Facon T; Harousseau JL; Tulliez M; Guerci A; Blaise D; Maloisel F; Michallet M; Andreesen R; Nerl C; Freund M; Gattermann N; Ehninger G; Deininger M; Ottmann O; Peschel C; Fruehauf S; Neubauer A; le Coutre P; Aulitzky W; Fanin R; Rosti G; Mandelli F; Lazzarino M; Morra E; Carella A; Petrini M; Nobile F; Liso V; Ferrara F; Rizzoli V; Fiortoni G; Martinelli G; Ossenkoppele G; Browett P; Gedde-Dahl T; Tangen JM; Dahl I; Odrizoala J; Hernandez Boulda JC; Steegman JL; Canizo C; Diaz J; Grenena A; Fernandez MN; Stenke L; Paul C; Bjoreman M; Malm C; Wadenvik H; Nilsson PG; Turesson I; Hess U; Solenthaler M; Clark RE; Green AR; Holyoake TL; Lucas GS; Smith G; Milligan DW; Rule SJ; Burnett AK; Moroose R; Wetzler M; Bearden J; Cataland S; Robinowitz I; Meisenberg B; Thompson K; Graziano S; Emanuel P; Gross H; Cobb P; Bhatia R; Dakhil S; Irwin D; Issell B; Pavletic S; Kuebler P; Layhe E; Butra P; Glass J; Moore J; Grant B; Neill H; Herzig R; Burris H; Petersen B; Kalaycio M; Stirewalt D; Samlowski W; Berman E; Limentani S; Seay T; Shea T; Akard L; Smith G; Becker P; Devine S; Hart R; Veith R; Wade J; Brunvad M; Kalman L; Strickland D; Shurafa M; Bashey A; Shadduck R; Safah H; Rubenstein M; Collins R; Keller A; Tallman M; Pecora A; Agha M; Homes H; Guidice R; Santini V. (2009). Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.. CANCER, vol. 115, pp. 551-560, ISSN:0008-543X DOI  

  Fenaux, P; Mufti, Gj; Hellstrom Lindberg, E; Santini, Valeria; Finelli, C; Giagounidis, A; Schoch, R; Gattermann, N; Sanz, G; List, A; Gore, Sd; Seymour, Jf; Bennett, Jm; Byrd, J; Backstrom, J; Zimmerman, L; Mckenzie, D; Beach, C; Silverman, Lr; Sacchi, S; Bosi, Alberto; Musto, P; Muus, P. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.. THE LANCET ONCOLOGY, vol. 10, pp. 223-232, ISSN:1470-2045

  Santini V (2009). Azacitidine in lower-risk myelodysplastic sindrome. LEUKEMIA RESEARCH, vol. 33Suppl2, pp. S22-S26, ISSN:0145-2126 DOI  

  V.Santini (2009). Azacitidine:activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. EXPERT REVIEW OF HEMATOLOGY, vol. 2, pp. 121-127, ISSN:1747-4086 DOI  

  Voso MT; Santini V; Finelli C; Musto P; Pogliani E; Angelucci E; Fioritoni G; Alimena G; Maurillo L; Cortelezzi A; Buccisano F; Gobbi M; Borin L; Di Tucci A; Zini G; Petti MC; Martinelli G; Fabiani E; Fazi. (2009). Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. CLINICAL CANCER RESEARCH, vol. 15, pp. 5002-5007, ISSN:1078-0432 DOI  

  Santini V (2009). Is survival enough for myelodysplastic syndromes?. LEUKEMIA RESEARCH, vol. 33(8), pp. 1017-1018, ISSN:0145-2126 DOI  

  Silverman LR; Fenaux P; Mufti GJ; Santini V; Hellström-Lindberg E; Gattermann N; Sanz G; List AF; Gore SD; Seymour JF; Backstrom J; McKenzie D; Beach CL. (2008). The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update.. ECANCERMEDICALSCIENCE, vol. 2, pp. 118-118, ISSN:1754-6605 DOI  

  Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V. (2008). Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. ONCOGENE, vol. 27, pp. 1767-78-1778, ISSN:0950-9232 DOI   Accesso ONLINE all'editore

  Maria Teresa Voso; Valeria Santini; Carlo Finelli; Lorenza Borin; Emanuele Angelucci; Giuseppe Fioritoni; Benedetta Neri; Agostino Cortellezi; Oreste Villani; Francesco Buccisano; Giovanni Martinelli; Maria Concetta Petti; Gina Zini; Alfonso Piciocchi; Paola Fazi; Giuliana Alimena; Marco Gobbi; Vincenzo Liso; and Giuseppe Leone (2008). 5-Azacytidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter TrialBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3648.. In: ASH, san francisco, 6-9 dicembre 2008, vol. 112, pp. 3648-3648. Accesso ONLINE all'editore

  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Guillermo Sanz; Alan F. List; Steven D. Gore; John F Seymour; Jay Backstrom; Linda Zimmerman; David McKenzie; C. L. Beach; and Lewis B. Silverman (2008). Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR). In: American society of hematology, american society of hematology, vol. 112, pp. 3636-3636. Accesso ONLINE all'editore

  Santini V.; Gozzini A.; Bosi A. (2008). Treatment options in myelodysplastic syndromes: a new frontier.. JOURNAL OF CHEMOTHERAPY, vol. 20(3), pp. 291-296, ISSN:1120-009X DOI  

  Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Sanz G; List AF; Gore SD; Seymour JF; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LB. (2008). Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update.. ECANCERMEDICALSCIENCE, vol. 2, pp. 121-121, ISSN:1754-6605

  Valeria Santini; Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Lewis B. Silverman; Alan List; Steven D. Gore; John F Seymour; Jay Backstrom; David McKenzie; and C. L Beach (2008). Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).. In: ASH, san francisco, 6-9 dicembre 2008, vol. 112, pp. 1653-1653.

  Elisabetta Antonioli; Paola Guglielmelli; Giada Poli; Costanza Bogani; Alessandro Pancrazzi; Giovanni Longo; Vanessa Ponziani; Lorenzo Tozzi; Lisa Pieri; Valeria Santini; Alberto Bosi; Alessandro M Vannucchi. (2008). Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.. HAEMATOLOGICA, vol. 93, pp. 41-48, ISSN:0390-6078 DOI  

  Luca Maurillo; Alessandra Spagnoli; Mariella Genuardi; Monia Lunghi; Nicola Di Renzo; Alfonso Maria D’Arco; Giuseppe Mele; Alessandro Levis; Antonella Gozzini; Mario Petrini; Manuela Mianulli; Grazia Sanpaolo; Alberto Santagostino; Giuseppe Pietrantuono; Fiorella D’Auria; Dario Ferrero; Gianluca Gaidano; Felicetto Ferrara; Adriano Venditti; Giuseppe Leone; Valeria Santini; and Pellegrino Musto (2008). 5-Azacytidine for the Treatment of Acute Myeloid Leukemia: A Retrospective, Multicenter Study of 55 Patients.. In: ASH, san franciscno, 6-9 dicembre 2008, vol. 112, pp. 1947-1947. Accesso ONLINE all'editore

  Pellegrino Musto; Luca Maurillo; Alessandra Spagnoli; Antonella Gozzini; Flavia Rivellini; Caterina Tatarelli; Monia Lunghi; Carla Fili; Enrico Orciuolo; Lucia Ciuffreda; Ernesto Vigna; Paola Della Cioppa; Anna Candoni; Dario Ferrero; Salvatore Palmieri; Giuseppe Palumbo; Nicola Di Renzo; Esther Oliva; Grazia Sanpaolo; Domenico Pastore; Anna Tonso; Alberto Santagostino; Stefano Rocco; Oreste Villani; Fiorella D’Auria; Alfonso Maria D’Arco; Gianluca Gaidano; Sara Galimberti; Domenico Russo; Adriano Venditti; Maria Antonietta Aloe-Spiriti; Giuseppe Leone; and Valeria Santini (2008). 5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program. In: ASH, san francisco, 6-9 dicembre 2008, vol. 112, pp. 2680-2680.

  Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A. (2008). The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 141, pp. 814-819, ISSN:0007-1048 DOI  

  Esther Natali e Oliva; Cristina Clissa; Valeria Santini; Antonella Poloni; Vincenzo Liso; Daniela Cilloni; Adelmo Terenzi; Stefana Impera; Alessandro Levis; Agostino Cortelezzi; Riccardo Ghio; Giampietro Semenzato; Oreste Villani; and Maria Antonietta Aloe Spiriti (2008). Quality of Life Assessment in Patients Affected by Myelodysplastic Syndrome. In: ASH, San Francisco, 6-9 dicembre 2008, vol. 112, pp. 2363-2363. Accesso ONLINE all'editore

  Simona Soverini; Alessandra Gnani; Sabrina Colarossi; Fausto Castagnetti; Francesca Palandri; Stefania Paolini; Cristina Papayannidis; Antonella Gozzini; Valeria Santini; Daniela Cilloni; Ester Orlandi; Serena Merante; Franca Radaelli; Michela Rondoni; Michele Malagola; Angela Poerio; Marilina Amabile; Ilaria Iacobucci; Gabriele Gugliotta; Gianantonio Rosti; Giovanni Martinelli; and Michele Baccarani (2008). Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.. In: ASH, san francisco, 6-9 dicembre 2008, vol. 112, pp. 2118-2118.

  John F Seymour; Pierre Fenaux; Lewis B. Silverman; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Alan F. List; Steven D. Gore; Jay Backstrom; David McKenzie; and C. L. Beach (2008). Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial. In: ASH, san francisco, 6-9 dicembre 2008, vol. 112, pp. 3629-3629. Accesso ONLINE all'editore

  JM. Bennett; V.Santini; MDS Foundation's Working Group on Transfusional Iron Overload (2008). Consensus statement on iron overload in myelodysplastic syndromes.. AMERICAN JOURNAL OF HEMATOLOGY, vol. 83, pp. 858-861, ISSN:0361-8609 DOI  

  Lewis R. Silverman; Pierre Fenaux; Ghulam J Mufti; Valeria Santini; Eva Hellström-Lindberg; Norbert Gattermann; Guillermo Sanz; Alan F. List; Steven D. Gore; John F Seymour; Jay Backstrom; David McKenzie; and C. L. Beach (2008). The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS). In: ASH, san francisco, 6-9 dicembre 2008, vol. 112, pp. 227-227. Accesso ONLINE all'editore

  Elisabetta Antonioli; Paola Guglielmelli; Giada Poli; Valeria Santini; Alberto Bosi; Alessandro M Vannucchi (2007). Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance.. BLOOD, vol. 110, pp. 4620-4621, ISSN:0006-4971 DOI  

  Ferrari G; Pastorelli R; Buchi F; Spinelli E; Gozzini A; Bosi A; Santini V. (2007). Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance.. JOURNAL OF PROTEOME RESEARCH, vol. 6, pp. 367-375, ISSN:1535-3893 DOI  

  V. SANTINI (2007). A selective activity of DNMTi decitabine on AML1ETO positive cells?. LEUKEMIA RESEARCH, vol. 31, pp. 741-742, ISSN:0145-2126, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010: DOI  

  Santini V; Gozzini A; Ferrari G. (2007). Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.. CURRENT DRUG METABOLISM, vol. 8, pp. 383-393, ISSN:1389-2002 DOI  

  V. Santini (2007). New treatments for myelodysplastic sindromes. In: American society of clinical oncology, 2007 educational book, pp. 383-383.

  V. Barbetti; A. Gozzini; E. Rovida; P. Dello Sbarba; P. Mascagni; V. Santini (2006). SPECIFIC DEGRADATION OF THE AML1-ETO/COREPRESSOR COMPLEX BY A NOVEL ORAL HYDROXAMIC ACID DERIVATIVE. HAEMATOLOGICA, vol. 91s3, pp. 28-29, ISSN:0390-6078

  E.Rovida; A.Gozzini; V.Barbetti; S.Giuntoli; V.Santini; P.Dello Sbarba (2006). The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 135, pp. 653-659, ISSN:0007-1048 DOI   Accesso ONLINE all'editore

  A. Gozzini; V. Barbetti; E. Rovida; S. Giuntoli; P. Dello Sbarba; V. Santini (2005). HDAC INHIBITORS IN COMBINATION WITH HYPOMETHYLATING AGENTS INDUCE SPECIFIC CHROMATIN MODIFICATION AND TRANSCRIPTIONAL ACTIVATION IN CBF/AML CELLS. HAEMATOLOGICA, vol. 90s3, pp. 78-79, ISSN:0390-6078

  Santoro L; Santini V; Di Lollo S; Valeri A; Colagrande S. (2005). Hemolymphangiomatosis of the spleen: imaging features.. JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, vol. 29, pp. 831-833, ISSN:0363-8715 DOI  

  Gozzini A;Santini V (2005). Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.. ANNALS OF HEMATOLOGY, vol. 84 Suppl 1, pp. 54-60, ISSN:0939-5555 DOI  

  V.Santini; M.A. Sekeres (2005). Azacitidine in myelodysplastic syndromes. DRUGS, vol. 65, pp. 1790-1791, ISSN:0012-6667

  Galimberti S;Guerrini F;Palumbo GA;Consoli U;Fazzi R;Morabito F;Santini V;Petrini M (2004). Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients.. LEUKEMIA RESEARCH, vol. 28, pp. 367-372, ISSN:0145-2126 DOI  

  E. Rovida; A. Gozzini; V. Barbetti; S. Giuntoli; V. Santini; P. Dello Sbarba (2004). MAPKS ARE INVOLVED IN THE SURVIVAL AND DIFFERENTIATION OF A T(8;21) ACUTE MYELOID LEUKEMIA CELL LINE AND ARE MODULATED BY THE HDAC INHIBITOR D1. HAEMATOLOGICA, vol. 89s6, pp. 96-96, ISSN:0390-6078

  Visani G;Isidori A;Grafone T;Tosi P;Santini V;Malagola M;Martinelli G;Piccaluga PP;Gaziev D;Ottaviani E;Sparaventi G;Tura S (2004). No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?. LEUKEMIA & LYMPHOMA, vol. 45, pp. 1361-1364, ISSN:1042-8194 DOI  

  V. Barbetti; E. Rovida; A. Gozzini; S. Giuntoli; V. Santini; P. Dello Sbarba (2004). EPIGENETIC MODIFICATIONS IN A T(8;21) ACUTE MYELOID LEUKEMIA CELL LINE CAUSED BY ADMINISTRATION OF THE HDAC INHIBITOR D1. HAEMATOLOGICA, vol. 89s6, pp. 93-94, ISSN:0390-6078

  Biscardi M;Caporale R;Pagliai G;Leoni F;Bernabei P;Santini V;Ciolli S;Grossi A (2003). In vitro antileukemic effect of a new anthracycline analogue, MEN 11079.. LEUKEMIA RESEARCH, vol. 27, pp. 1125-1134, ISSN:0145-2126

  V. Santini; G.Longo (2003). Anemie. In: C.Bartoli, GF.Gensini,G. Laffi,G. Lucivero, B. Trimarco. Medicina Interna, pp. 1575-1596, Napoli (Italy), Reddick, FL (USA): Gruppo Editoriale IDELSON-GNOCCHI srl.

  V. Santini (2003). Sindrome mielodisplstiche. In: C. Bartoli, GF. Gensini,G. Laffi, G. Lucivero, B. Trimarco. Medicina Interna, pp. 1601-1606, Napoli (Italy), Reddick, FL (USA): Gruppo Editoriale IDELSON-GNOCCHI srl.

  A.GOZZINI; E.ROVIDA; P.DELLO SBARBA; S.GALIMBERTI; V. SANTINI (2003). Butyrates as single drug induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts.. CANCER RESEARCH, vol. 63, pp. 8955-8961, ISSN:0008-5472 Accesso ONLINE all'editore

  V. Santini (2003). Malattie Linfoproliferative Croniche. In: C. Bartoli, GF. Gensini,G. Laffi,G. Lucivero, R.Trimarco. Medicina Interna, pp. 1643-1648, Napoli (Italy), Reddick, FL (USA): Gruppo Editoriale IDELSON-GNOCCHI srl.

  Galimberti S;Rossi A;Palumbo GA;Morabito F;Guerrini F;Vincelli I;Fazzi R;Santini V;Petrini M (2003). FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia.. ANTICANCER RESEARCH, vol. 23, pp. 3419-3426, ISSN:0250-7005

  V. SANTINI; SCAPPINI B; INDIK ZK; GOZZINI A; ROSSI FERRINI P; SCHREIBER AD (2003). The carboxyterminal region of G-CSF -R transduces a phagocytic signal. BLOOD, vol. 101, pp. 4615-4622, ISSN:0006-4971

  MONICI M; AGATI G; F. FUSI; R.PRATESI ; PAGLIERANI M; V.SANTINI ; BERNABEI PA (2003). Dependence of leukemic cell autofluorescence patterns on the degree of differentiation. PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES, vol. 2, pp. 981-987, ISSN:1474-905X DOI  

  V. Santini (2003). Leucemie Acute. In: C. Bartoli, GF. Gensini,G. Laffi;G. Lucivero, B. Trimarco. Medicina Interna, pp. 1607-1614, Napoli (Italy), Reddick, FL (USA): Gruppo Editoriale IDELSON-GNOCCHI srl.

  A. Gozzini; E. Rovida; A Pratesi; P. Dello Sbarba; P Rossi Ferrini; V. Santini (2002). ACETYLATION INDUCED BY BUTYRATES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA CAN LEAD TO DIFFENTIATION. HAEMATOLOGICA, vol. 87, pp. 119-119, ISSN:0390-6078

  V. SANTINI; SCAPPINI B; GROSSI A; GOZZINI A; BONSI L; PAGLIAI G; ROSSI FERRINI P; BAGNARA GP. (2002). Lyn kinase is activated following thrombopoietin stimulation of the megakaryocytic cell line B1647. Haematologica. 2002 Dec;87(12):1242-7.. HAEMATOLOGICA, vol. 12, pp. 1242-1247, ISSN:0390-6078, Fondaz Ferrata Storti:Strada Nuova 134, 27100 Pavia Italy:011 39 0382 531182, EMAIL: office@haematologica.it, Fax: 011 39 0382 27721:

  GROSSI A; MUSTO P; V. SANTINI; BALESTRI F; FABBRI A; FALCONE A; SANPAOLO G. (2002). Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.. HAEMATOLOGICA, vol. 3, pp. 322-323, ISSN:0390-6078, Fondaz Ferrata Storti:Strada Nuova 134, 27100 Pavia Italy:011 39 0382 531182, EMAIL: office@haematologica.it, Fax: 011 39 0382 27721:

  V. SANTINI; GOZZINI A; SCAPPINI B; GROSSI A; ROSSI FERRINI P. (2001). Searching for the magic bullet against cancer: the butyrate saga.. LEUKEMIA & LYMPHOMA, vol. 3, pp. 275-289, ISSN:1042-8194

  KANTARJIAN HM; TALPAZ M; V. SANTINI; MURGO A; CHESON B; O'BRIEN SM. (2001). Homoharringtonine: history, current research, and future direction.. CANCER, vol. 6, pp. 1591-1605, ISSN:0008-543X DOI  

  F. LEONI; S. CIOLLI; C. NOZZOLI; V. SANTINI; R. FANCI; P. ROSSI FERRINI (2001). FLUDARABINE, CYTARABINE AND TOPOTECAN (FLAT) AS INDUCTION THERAPY FOR ACUTE MYELOID LEUKEMIA IN THE ELDERLY: A PRELIMINARY REPORT. HAEMATOLOGICA, vol. 86, pp. 104-110, ISSN:0390-6078

  V.Santini (2001). Amifostine: chemotherapeutic and radiotherapeutic protective effects. EXPERT OPINION ON PHARMACOTHERAPY, vol. 2, pp. 479-489, ISSN:1744-7666 DOI  

  V. SANTINI; KANTARJIAN HM; ISSA JP. (2001). Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.. ANNALS OF INTERNAL MEDICINE, vol. 7, pp. 573-586, ISSN:0003-4819

  GROSSI A; FABBRI A; V. SANTINI; LEONI F; NOZZOLI C; LONGO G; PAGLIAI G; CIOLLI S; ROSSI FERRINI P. (2000). Amifostine in the treatment of low-risk myelodysplastic syndromes.. HAEMATOLOGICA, vol. 4, pp. 367-371, ISSN:0390-6078

  V. SANTINI; GOZZINI A; SCAPPINI B; ROSSI FERRINI P. (1999). Maturation and apoptosis of primary human acute myeloblastic leukemia cells are determined by TNF-alpha exclusively through CD120A stimulation.. HAEMATOLOGICA, vol. 4, pp. 291-297, ISSN:0390-6078

  Giles FJ;O'Brien SM;Santini V;Gandhi V;Plunkett W;Seymour JF;Robertson LE;Kantarjian HM;Keating MJ (1999). Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.. LEUKEMIA & LYMPHOMA, vol. 36, pp. 57-65, ISSN:1042-8194 DOI  

  Pouillart P;Douillet O;Scappini B;Gozzini A;Santini V;Grossi A;Pagliai G;Strippoli P;Rigacci L;Ronco G;Villa P (1999). Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: influence of alkyl chain length on acute toxicity.. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 7, pp. 93-106, ISSN:0928-0987

  Alterini R;Rigacci L;Stefanacci S;Innocenti F;Santini V;Carrai V;Rossi Ferrini P (1999). Immunohistochemistry applied to the study of bone marrow Gaucher's cells: a case report.. EUROPEAN JOURNAL OF HISTOCHEMISTRY, vol. 43, pp. 235-239, ISSN:1121-760X

  V. SANTINI; GILES FJ. (1999). The potential of amifostine: from cytoprotectant to therapeutic agent. HAEMATOLOGICA, vol. 11, pp. 1035-1042, ISSN:0390-6078

  V. SANTINI; GOZZINI A; SCAPPINI B; CAPORALE R; ZOCCOLANTE A; RIGACCI L; GELARDI E; GROSSI A; ALTERINI R; FERRINI PR. (1999). Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells.. HAEMATOLOGICA, vol. 10, pp. 897-904, ISSN:0390-6078

  Monici M;Fusi F;Mazzinghi P;Degli Innocenti o Nocentini A;Landini I;Banchelli I;Bartolozzi B;Santini V;Bernabei PA (1999). Natural fluorescence imaging of leukemic cells for studying uptake and retention of anthracyclines.. In: Kaspers G.J.L., Pieters R., Veerman A.J.P.. Drug Resistance in Leukemia and Lymphoma III., pp. 89-94, Boston, MA: Springer, ISBN:978-1-4613-7180-9. DOI   Accesso ONLINE all'editore

  Bernabei PA;Landini I;Bartolozzi B;Banchelli I;Degli Innocenti o Nocentini A;Santini V;Ematologia UO (1999). Activity of vinorelbine on B-chronic lymphocytic leukemia cells in vitro.. In: Bernabei PA. Adv Exp Med Biol, pp. 473-476 Springer. DOI  

  Grossi A;Nozzoli C;Gheri R;Santini V;Marrani C;Zoccolante A;Ferrini PR (1998). Pure red cell aplasia in autoimmune polyglandular syndrome with T lymphocytosis.. HAEMATOLOGICA, vol. 83, pp. 1043-1045, ISSN:0390-6078

  V. SANTINI; ROSSI FERRINI P. (1998). Differentiation therapy iof myelodysplastic syndromes : facts or fiction ?. BRITISH JOURNAL OF HAEMATOLOGY, vol. 102, pp. 1124-1138, ISSN:0007-1048 DOI  

  de Koning JP;Soede-Bobok AA;Schelen AM;Smith L;van Leeuwen D;Santini V;Burgering BM;Bos JL;Lowenberg B;Touw IP (1998). Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor.. BLOOD, vol. 91, pp. 1924-1933, ISSN:0006-4971

  S. Linari; A. M. Vannucchi; S. Ciolli; F. Leoni; R. Caporale; A. Grossi; G. Pagliai; V. Santini; F. Paoletti; P. R. Ferrini (1998). Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 102, pp. 1335-1337, ISSN:0007-1048

  V. SANTINI; SCAPPINI B; GOZZINI A; GROSSI A; VILLA P; RONCO G; DOUILLET O; POUILLART P; BERNABEI PA; ROSSI FERRINI P. (1998). Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 3, pp. 529-538, ISSN:0007-1048

  Santini V;Bernabei A;Gozzini A;Scappini B;Zoccolante A;D'Ippolito G;Figuccia M;Ferrini PR (1997). Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders.. HAEMATOLOGICA, vol. 82, pp. 11-15, ISSN:0390-6078

  Gaidano G;Pastore C;Santini V;Nomdedeu J;Gamberi B;Capello D;Vischia F;Resegotti L;Mazza U;Ferrini PR;Lo Coco F;Saglio G (1997). Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia.. GENES, CHROMOSOMES & CANCER, vol. 19, pp. 250-255, ISSN:1045-2257

  Santini V;D'Ippolito G;Bernabei PA;Zoccolante A;Ermini A;Rossi-Ferrini P (1996). Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.. LEUKEMIA RESEARCH, vol. 20, pp. 37-45, ISSN:0145-2126

  V. Santini; A. Zoccolante; A. Bosi; S. Guidi; R. Saccardi; A. M. Vannucchi; G. Martinazzo; P. A. Bernabei; P. R. Ferrini (1996). Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.. HAEMATOLOGICA, vol. 81, pp. 201-207, ISSN:0390-6078

  Santini V;Lamberts SW;Krenning EP;Backx B;Löwenberg B (1995). Somatostatin and its cyclic octapeptide analog SMS 201-995 as inhibitors of proliferation of human acute lymphoblastic and acute myeloid leukemia.. LEUKEMIA RESEARCH, vol. 19, pp. 707-712, ISSN:0145-2126

  QUATTRONE A; PAPUCCI L; SANTINI V; N. SCHIAVONE; NOFERINI D; CALASTRETTI A; COPRENI E; MORELLI S; ROSSI FERRINI PL; NICOLIN A; CAPACCIOLI S (1995). Quantitation of bcl-2 oncogene in cultured lymphoma/leukemia cell lines and in primary leukemia B-cells by a highly sensitive RT-PCR method.. HAEMATOLOGICA, vol. 80, pp. 495-504, ISSN:0390-6078 Accesso ONLINE all'editore

  Orlandini SZ;Formigli L;Benvenuti S;Lasagni L;Franchi A;Masi L;Bernabei PA;Santini V;Brandi ML (1995). Functional and structural interactions between osteoblastic and preosteoclastic cells in vitro.. CELL AND TISSUE RESEARCH, vol. 281, pp. 33-42, ISSN:0302-766X, Springer Verlag Germany:Tiergartenstrasse 17, D 69121 Heidelberg Germany:011 49 6221 3450, EMAIL: g.braun@springer.de, INTERNET: http://www.springer.de, Fax: 011 49 6221 345229:

  Rossi Ferrini P; Santini V; Ciolli S; Grossi A; Leoni F; Rafanelli D; Vannucchi AM. (1993). The role of haematopoietic growth factors in the treatment of myelodysplastic syndromes.. HEMATOLOGICAL ONCOLOGY, vol. 11, pp. 32-35, ISSN:0278-0232

  LOWENBERG B; VAN PUTTEN WL; TOUW IP; DELWEL R; V. SANTINI (1993). Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia.. THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 4, pp. 614-619, ISSN:0028-4793 DOI  

  TOUW I; DONATH J; POUWELS K; VAN BUITENEN C; SCHIPPER P; V. SANTINI; HAGEMEIJER A; LOWENBERG B; DELWEL R. (1991). Acute myeloid leukemias with chromosomal abnormalities involving the 21q22 region identified by their in vitro responsiveness to interleukin-5.. LEUKEMIA, vol. 8, pp. 687-692, ISSN:0887-6924

  V. SANTINI; COLOMBAT P; DELWEL R; VAN GURP R; TOUW I; LOWENBERG B. (1991). INDUCTION OF GRANULOCYTIC MATURATION IN ACUTE MYELOID LEUKEMIA BY G-CSF AND RETINOIC ACID.. LEUKEMIA RESEARCH, vol. 5, pp. 341-350, ISSN:0145-2126 DOI  

  COLOMBAT P; V. SANTINI; DELWEL R; KREFFT J; BREDMOND JL; LOWENBERG B. (1991). Primary human acute myeloblastic leukaemia: an analysis of in vitro granulocytic maturation following stimulation with retinoic acid and G-CSF.. BRITISH JOURNAL OF HAEMATOLOGY, vol. 3, pp. 382-389, ISSN:0007-1048 DOI  

  Bernabei PA;Ermini A;Santini S;Santini V;Fossombroni V;Rossi Ferrini P (1991). Effect of (dl)-5-methyltetrahydrofolate on acute non-lymphocytic leukemia cells in primary culture.. JOURNAL OF CHEMOTHERAPY, vol. 3, pp. 255-259, ISSN:1120-009X

  BERGAMASCHI G; CAZZOLA M; ROSTI V; CARLO-STELLA C; V. SANTINI; PONCHIO L; PEVERALI FA; DELLA VALLE G; ROSSI FERRINI P; ASCARI E. (1991). Tumor necrosis factor alpha modulates the messenger RNA expression of hematopoietic growth factor genes in fresh blast cells from patients with acute myeloblastic leukemia.. LEUKEMIA, vol. 10, pp. 886-891, ISSN:0887-6924, Macmillan Magazines Limited:Porters South Crinian Street, London N1 9XW United Kingdom:011 44 207 8334000, 011 44 171 8434982, Fax: 011 44 207 812358:

  V. SANTINI; NOOTER K; DELWEL R; LOWENBERG B. (1990). Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): assessment in vitro after stimulation with colony stimulating factors (CSFs).. LEUKEMIA RESEARCH, vol. 4, pp. 377-380, ISSN:0145-2126 DOI  

  Dal Pozzo O;Santini V;Saccardi R;Bernabei PA;Rossi Ferrini P (1990). Assessment of PTT 119 activity on acute nonlymphoblastic leukemia cells by [3H]-thymidine uptake inhibition and cluster analysis.. HAEMATOLOGICA, vol. 75, pp. 50-53, ISSN:0390-6078

  Santini V; Bernabei PA; Silvestro L; Dal Pozzo O; Bezzini R; Viano I; Gattei V; Saccardi R; Ferrini PR. (1989). In vitro chemosensitivity testing of leukemic cells: prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia.. HEMATOLOGICAL ONCOLOGY, vol. 7, pp. 287-293, ISSN:0278-0232

  P. A. Bernabei; E. Mini; V. Gattei; F. C. Agostino; R. Bezzini; R. Saccardi; V. Santini; M. Coronnello; T. Mazzei; P. Rossi Ferrini (1989). Induction of differentiation of HL-60 cells along the monocytic pathway by 5-methyltetrahydrofolate.. JOURNAL OF CHEMOTHERAPY, vol. 1, pp. 359-364, ISSN:1120-009X

  Dal Pozzo O;Bernabei PA;Santini V;Saccardi R;Santini S;Rossi Ferrini P (1989). A comparison of two assays for the in vitro chemosensitivity testing of human acute non-lymphoblastic leukemia cells.. JOURNAL OF CHEMOTHERAPY, vol. 1, pp. 318-323, ISSN:1120-009X

  BERNABEI PA; V. SANTINI; SILVESTRO L; DAL POZZO O; BEZZINI R; VIANO I; GATTEI V; SACCARDI R; ROSSI FERRINI P. (1989). IN VITRO CHEMOSENSITIVITY TESTING OF LEUKEMIC CELLS: DEVELOPMENT OF A SEMIAUTOMATED COLORIMETRIC ASSAY.. HEMATOLOGICAL ONCOLOGY, vol. 3, pp. 243-253, ISSN:0278-0232 DOI  

  P. Rossi Ferrini; A. Grossi; V. Santini; A. M. Vannucchi (1989). [GM-CSF: its clinical administration; the treatment of aplasia]. HAEMATOLOGICA, vol. 74, pp. 489-500, ISSN:0390-6078

  V. SANTINI; BERNABEI PA; SILVESTRO L; DAL POZZO O; BEZZINI R; VIANO I; GATTEI V; SACCARDI R; FERRINI PR. (1989). LEUKEMIC CELLS: PREDICTION OF RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA.. HEMATOLOGICAL ONCOLOGY, vol. 4, pp. 287-293, ISSN:0278-0232, John Wiley & Sons Limited:1 Oldlands Way, Bognor Regis, P022 9SA United Kingdom:011 44 1243 779777, EMAIL: cs-journals@wiley.co.uk, INTERNET: http://www.wiley.co.uk, Fax: 011 44 1243 843232:

  BERNABEI PA; ROMBOLA G; SACCARDI R; BEZZINI R; V. SANTINI; PIFFERI C; GATTEI V; FERRINI PR. (1988). Scheduling-dependent interaction for the combination of cytosine arabinoside and daunorubicin on HL-60 cells.. HAEMATOLOGICA, vol. 6, pp. 466-470, ISSN:0390-6078, Fondaz Ferrata Storti:Strada Nuova 134, 27100 Pavia Italy:011 39 0382 531182, EMAIL: office@haematologica.it, Fax: 011 39 0382 27721:

  Bernabei PA;Santini V;Dal Pozzo O;Bezzini R;Gattei V;Saccardi R;Rombolà G;Ferrini PR (1988). Clonogenic growth of acute non-lymphocytic leukemia cells in serum-free medium.. EXPERIENTIA, vol. 44, pp. 903-906, ISSN:0014-4754

  Bernabei PA;Agostino FC;Bezzini R;Saccardi R;Gattei V;Santini V;Casini M;Rossi Ferrini P (1988). Proliferation and cell loss of human leukemic cell subpopulations in liquid culture.. EXPERIENTIA, vol. 44, pp. 245-247, ISSN:0014-4754